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ABSTRACT 
 
Immunotherapy utilizing cytokines or immune regulatory check point blockade has consistently 
demonstrated superior clinical efficacy in melanoma when compared to tumor peptide 
immunization strategies reported to date. In this project, I conducted 2 model studies 
representing alternative immunotherapeutic approaches (non-antigen specific combination of 
interferon-α2b and an anti-CTLA4 monoclonal antibody, IFN-Treme compared to a tumor 
antigen specific multi-epitope vaccine given in adjuvant with the potent combination of a TLR-9 
agonist and GM-CSF) designed to overcome tumor immune evasion and conducted separately in 
a similar patient population. In addition to evaluating safety and clinical efficacy, I tested the 
following hypotheses: (1) Clinical benefits are likely to be associated with markers of reversal of 
immune tolerance (autoimmunity). (2) Clinical benefits may be predicted by baseline peripheral 
biomarkers of immune tolerance/suppression (C-reactive protein, CRP and absolute lymphocyte 
count, ALC). (3) Superior antitumor efficacy is likely to be associated with more effective 
downregulation of the host suppressor immune response (circulating T regulatory cells, T-reg 
and myeloid derived suppressor cells, MDSC). My findings supported superior clinical efficacy 
that was associated with more significant modulation of immune tolerance by the combination of 
IFN-Treme. Autoimmunity correlated with improved clinical outcome among the recipients of 
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IFN-Treme (but not the vaccine) and suggested more significant reversal of immune tolerance. 
Baseline CRP and ALC were significantly predictive of therapeutic benefit with the IFN-Treme 
combination and may serve as variables for stratification of future trials, as these are validated in 
larger studies. Finally, my findings supported more significant downregulation of the host 
suppressor immune response by the nonspecific IFN-α/Treme regimen as compared to the 
vaccine-TLR agonist/GM-CSF combination. There was apparent increase in CD4+CD25hi+ 
CD39+ Treg but this was associated with an increase in the overall CD4+ T cell population 
suggesting that direct inhibition of CTLA4 suppressive effects on T effector cells leading to their 
expansion and prolonged activation is likely more important than the regimen’s effect on T-reg. 
In addition, I saw parallel downregulation in several populations of MDSC following treatment 
with IFN-Treme which may have had a role in the reduction of immune suppression and superior 
clinical outcome observed. 
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1.0  INTRODUCTION 
By the time melanoma has become clinically detectable, the theory of immunoediting holds 
that the tumor has already evolved mechanisms to evade the immune response mounted by the 
host against it. If the goal of treating melanoma is to achieve cure/clinically durable benefits 
through the creation of lasting anti-tumor immunity, then immunotherapy that is meant to unlock 
the immune response and key regulators of immune tolerance must be central to experimental 
therapeutic strategies targeting this disease. In addition, testing biomarkers predictive of 
immunotherapeutic benefits must be integral to our clinical testing, allowing us to define what 
patients have the capacity to develop anti-melanoma immunity in response to certain 
immunotherapeutics. 
In our efforts to build upon the success of current immunotherapeutic strategies, it is well 
supported that the induction of effective antitumor immunity in patients with cancer will likely 
require approaches aiming at the elicitation of anti-tumor immune responses using vaccines 
combined with potent immunological adjuvants allowing the slow release of antigen and 
increasing the presentation of antigens by APCs to immune cells or using ex-vivo generated 
dendritic cell (DC) vaccine strategies. Our approaches should aim at the protection of anti-tumor 
immune cells from the inhibiting effects of myeloid-derived suppressor cells (MDSCs), 
regulatory T cells (T-regs) or tumor derived inhibitory factors thus enhancing effector functions 
utilizing cytokines, antibodies and cellular therapies.1 In addition, our strategies should be aimed 
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at prolonging survival of central memory T cells, thus ensuring long-term protection where 
monoclonal antibodies (mAbs) that target immunoregulatory checkpoints that are able to 
suppress/enhance host responses to tumor associated antigens (TAAs) may play a central role. 2 
Our current clinical experience is that non-tumor specific immunotherapy utilizing 
interleukin-2 (IL-2) and more recently ipilimumab (for metastatic melanoma) and interferon-α 
(for surgically resected melanoma) have produced the most significant results in the management 
of this disease leading to regulatory approval.3-5 On the other hand, results from antigen specific 
immunization modalities have been modest and have not yet translated into meaningful clinical 
benefits. These include peptide vaccines designed to increase immune recognition of tumor cells 
and to enhance the antitumor effector immune response through lymphocyte activation.3, 6, 7 In 
this project, I have conducted and compared 2 model studies representing alternative 
immunotherapeutic approaches (non-antigen specific compared to tumor antigen specific) meant 
to overcome tumor immune evasion and conducted separately in a similar patient population. In 
addition, I pursued the evaluation of select correlate biomarkers of immune tolerance and its 
reversal and immune monitoring of the host suppressor cellular response within both studies to 
better understand our clinical observations. 
Therefore, I have focused on 2 immunotherapeutic approaches to overcoming melanoma 
immune tolerance utilizing a tumor-antigen specific approach in one and a non-antigen specific 
approach in the other. I divided this project into 3 main components: (1) combination biotherapy 
of interferon (IFN)α-2b and Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) blockade with 
tremelimumab mAb (IFN-Treme) as non-tumor antigen specific immunotherapy for advanced 
melanoma. (2) Peptide vaccination against melanoma lineage antigens given in adjuvant with the 
Toll-Like Receptor 9 (TLR-9) agonist PF-3512676 and GM-CSF given locally in-oil adjuvant 
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with the peptides (vaccine). (3) Nested within both studies, I pursued the testing of mechanistic 
analyses and biomarkers of therapeutic benefit and reversal of immune tolerance of melanoma, 
including (a) non-tumor specific biomarkers of immune tolerance or suppression and their 
reversal (induced autoimmunity, CRP, ALC and other candidate cytokines and chemokines), (b) 
differential modulation of the host suppressor cellular response by monitoring circulating T-regs 
and MDSCs by CTLA4 blockade/IFN-α as compared to vaccination combined with TLR-9 /local 
GM-CSF adjuvants. My central hypothesis is that both immunotherapeutic strategies (IFN-
Treme and vaccine) may overcome tumor-induced immune suppression as demonstrated both 
clinically and immunologically in the 2 trials that enrolled a similar patient population with 
advanced inoperable stage III and stage IV melanoma: 
1. Clinical benefits would be associated with serologic/clinical markers of reversal of immune 
tolerance (autoimmunity): Induction of autoimmunity correlates with clinical benefits. 
2. Clinical benefits may be predicted by baseline peripheral biomarkers of immune 
suppression (CRP, ALC): Enhanced immune suppression correlates with a lower likelihood 
of response. 
3. Superior clinical activity (with one regimen as compared to the other) would be associated 
with more effective downregulation of the host suppressor cellular immune response. 
1.1 METASTATIC MELANOMA 
For patients with advanced melanoma, immunological approaches have yielded the only 
newly US-FDA approved agents in over 30 years, high-dose interleukin-2 (IL-2) (for metastatic 
melanoma) and interferon (IFN)-α (for surgically resected melanoma) that have produced the 
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most promising and durable results, albeit in subgroups of patients only 8. Although promising, 
clinical benefits from current investigational agents appear to be of either limited duration and/or 
confined to small groups of patients.  Therefore, there continues to be an urgent need for new 
therapeutic strategies building upon promising clinical activity and solid preclinical rationale. 
1.2 IMMUNITY IN MELANOMA, THE ROLE OF IMMUNE TOLERANCE IN 
ADVANCED METASTATIC DISEASE AND IMPLICATIONS FOR 
IMMUNOTHERAPY 
Immunity to melanoma appears to be important for disease control in the adjuvant and 
advanced disease settings. Spontaneous regression of disease has been reported in patients with 
melanoma, suggesting a role for host immunity, indirectly supported by the pathological 
evidence for the presence of lymphoid infiltrates at primary melanoma associated with tumor 
regression. T-cell infiltrates in primary melanoma have been suggested to be of prognostic 
significance, and T-cell infiltrates within regional nodal metastases predict benefit in patients 
treated with neoadjuvant IFNα2b therapy.9-13 In advanced melanoma, the quality of the host 
immune response has been shown to be compromised, with evidence of displaying strong 
melanoma antigen-specific Th2-type polarization14, yielding a microenvironment that facilitates 
disease progression.15 Therefore, host immune tolerance appears to be an impediment to the 
therapy of advanced disease. 
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1.3 STRATEGIES FOR OVERCOMING TUMOR-INDUCED IMMUNE 
SUPPRESSION AND RATIONALE FOR OUR SELECTED APPROACHES  
The principles that guide the development and application of immunotherapy in 
melanoma are vast and include antibodies, cytokines, and cellular therapies. Enhanced 
expression of costimulatory molecules on the surface of dendritic cells (DCs) is one approach to 
enhance presentation of tumor-associated antigens (APCs). This can be achieved through 
stimulation of DC receptors such as TLR-9 and CD40.16-18 Another approach is to enhance or 
prolong T-cell activation by blocking negative signaling receptors such as CTLA4.19 Other 
approaches in clinical investigation include overcoming indoleamine deoxygenase and 
programmed death ligand 1 (PD-1) or adding costimulatory functions (4-1BB/anti-CD137). 
Other key approaches to overcoming melanoma tolerance and eliciting antitumor immune 
responses are cancer vaccines designed to increase immune recognition of tumor cells and to 
enhance the antitumor effector immune response through lymphocyte activation.7 These include 
ex-vivo generated DC-based vaccination and other melanoma specific vaccines comprised of 
whole tumor cells, tumor-cell lysates or specific peptides. This is in addition to DNA vaccines, 
heat shock proteins (HSPs) and gene therapy. 
 
2.0 STATEMENT OF PROBLEM 
 
Non-tumor specific immunotherapy utilizing interleukin-2 (IL-2) and more recently 
ipilimumab (for metastatic melanoma) and interferon-α (for surgically resected melanoma) have 
produced the most significant results in the management of this disease leading to regulatory 
approval.3-5 On the other hand, results from antigen specific immunization modalities have been 
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modest and have not yet translated into meaningful clinical benefits. These include peptide 
vaccines designed to increase immune recognition of tumor cells and to enhance the antitumor 
effector immune response through lymphocyte activation.3, 6, 7 In this project, I have conducted 
and compared 2 model studies representing alternative immunotherapeutic approaches (non-
antigen specific compared to tumor antigen specific) meant to overcome tumor immune evasion 
and conducted separately in a similar patient population of advanced inoperable stage III and 
stage IV melanoma. In addition, I pursued the evaluation of select correlate biomarkers of 
immune tolerance and its reversal and immune monitoring of the host suppressor cellular 
response within both studies to better understand our clinical observations. Therefore, I tested the 
following: 
A. Safety and efficacy of combination biotherapy of IFNα-2b and CTLA-4 blockade with 
tremelimumab in patients with inoperable AJCC stage III and stage IV melanoma (N=37 
patients), as a non-tumor antigen specific immunotherapeutic approach. 
B. Safety and immunogenicity of multi-epitope peptide vaccination with MART-1 (26-35, 27L), 
gp100 (209-217, 210M), and tyrosinase (368-276, 370D) peptides given locally in oil 
adjuvant with the combination of TLR-9 agonist PF-3512676 and GMCSF in patients with 
inoperable AJCC stage III and stage IV melanoma (N=20), as an antigen specific 
immunotherapeutic approach. 
C. A mechanistic and biomarker analysis of prognostic and therapeutic predictive biomarkers, 
nested within both studies, including 
a. The association of clinical benefits with serologic/clinical markers of reversal of 
immune tolerance (autoimmunity): Induction of autoimmunity correlates with clinical 
benefits. 
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b. The association of clinical benefits with baseline peripheral biomarkers of immune 
suppression (CRP, ALC): Enhanced immune suppression correlates with a lower 
likelihood of response. 
c. Whether superior clinical activity would be associated with more effective 
downregulation of the host suppressor cellular immune response. 
 
3.0 HYPOTHESES 
 
A. The combination of IFNα-2b and CTLA-4 blockade with tremelimumab as tested in a 
phase II clinical trial is safe and will improve the response rate (RECIST criteria), 
progression free survival (PFS), overall survival (OS) and the one-year survival rate 
(analyzed according to Korn et.al.20) in patients with inoperable AJCC stage III and stage 
IV melanoma, as a therapeutic strategy to overcome melanoma immune tolerance. 
B. Vaccination with the multi-epitope vaccine containing MART-1 (26-35, 27L), gp100 
(209-217, 210M), and tyrosinase (368-276, 370D) peptides given in oil adjuvant with the 
combination of TLR-9 agonist PF-3512676 and GMCSF is safe and will enhance 
immunogenicity as measured by the frequency of antigen-specific CD8+ T cell responses 
(measured by ELIspot assay). It will improve the response rate (RECIST criteria), PFS 
and OS.  
C. The clinical benefits as measured by response rate (PR, CR) and disease control rate (SD, 
PR, CR) of immunotherapy in both studies, will be significantly associated with the 
induction of autoimmunity, as a marker of reversing immune tolerance.  
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D. The clinical benefits as measured by response rate (PR, CR) and disease control rate (SD, 
PR, CR) can be significantly predicted by baseline nonspecific candidate biomarkers 
associated with immune tolerance (namely CRP, ALC). 
E. Superior clinical activity (of one regimen compared to the other) will be associated with 
more significant modulation/downregulation of the host suppressor cellular immune 
response. 
4.0 FIRST CHAPTER: COMBINATION IMMUNOTHERAPY WITH 
INTERFERON-ALFA AND CTLA4 BLOCKADE 
 
4.1 CTLA-4 BLOCKADE WITH TREMELIMUMAB AND RATIONALE FOR 
TESTING IT IN COMBINATION WITH IFN-Α IN ADVANCED MELANOMA 
CTLA4 is a key element in immune tolerance and the main negative regulator of T cell-
mediated antitumor immune responses.21 Early preclinical studies suggested that this molecule 
serves as a natural braking mechanism for T-cell activation, allowing a return to homeostasis 
following an immune response.22-24 CTLA4 is a homologue of CD28 that functions as an 
inhibitory receptor for B7 costimulatory molecules expressed on mature APCs.25, 26 Following T-
cell activation, CTLA4 cell-surface receptors are up-regulated and successfully compete with 
CD28 for binding to B7, sending an inhibitory signal that down-regulates T-cell activation.19, 26 
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This inhibitory signal affects downstream targets of CTLA4 that include cytokine production by 
Th1 and Th2 cells27 and key components of the cell cycle machinery (Cdk-4, Cdk-6, and cyclin 
D3) required for cell cycle progression.28-30 Anti-CTLA4 mAbs with a much greater affinity for 
CTLA4 than B7 (competitive inhibition) were cloned and shown to inhibit the interaction of B7 
and CTLA4.19 The inhibitory signal produced by CTLA4 is therefore blocked, and T-cell 
activation is enhanced (i.e., releasing the brake). In vitro and in vivo, anti-CTLA4 mAbs were 
shown to enhance T-cell function.25, 27, 31-33 Recently, CTLA4 blocking antibodies (Ipilimumab 
and Tremelimumab) have shown promising and durable clinical activity as monotherapy, but 
only in a fraction of patients34, 35. There is, therefore, an urgent need to build upon the limited 
success of tremelimumab through novel combination therapeutic strategies. 
 IFNα-2b, a type I IFN, is a highly pleiotropic cytokine with potent 
immunoregulatory, antiproliferative, differentiation-inducing, apoptotic, and anti-angiogenic 
properties in a variety of malignancies 36. Type I IFNs exert their effects through a common 
receptor, termed type I IFN receptor (IFNA-R), which predominantly mediates its effects via the 
Janus family kinases (JAK)/signal-transducers and activators of transcription protein (STATs) 
transduction pathway 37. IFN-α has been shown to induce important changes in JAK-STAT 
signaling in malignancies including melanoma.38-42 In a neoadjuvant study of high dose IFNα-2b 
(HDI), clinical responders had significantly greater increases in endotumoral CD11c+ and CD3+ 
cells.13 In the adjuvant melanoma setting, HDI has shown consistent durable relapse-free and 
overall survival impact as tested in 3 randomized controlled trials and is the current FDA 
approved standard of care. 43-45  
 The immunological impact of IFNα in overcoming immune tolerance of 
melanoma is widely supported including clinical evidence of upregulation of the pro-
 10 
inflammatory cytokine response (Th1 polarization) as demonstrated in the adjuvant E1694 trial.46 
Moreover, the impact of IFNα on DCs is well established, affecting almost all stages of myeloid 
DC generation, maturation, differentiation and function 47. In addition, in their immature state, 
IFN-treated DCs induce a ‘polarized’ Th1 cytokine microenvironment 48. Similar to myeloid 
DCs, IFNs polarize lymphocytes towards the pro-inflammatory Th1 phenotype 49-51. In the 
cytotoxic T cell compartment, type I IFNs induce potent antitumoral cell-mediated cytotoxicity 
52, and they promote natural killer (NK) cell-mediated proliferation and cytotoxicity 53. This Th1 
shift in immunity induced by IFN-α may, however, still be suppressed explaining the limited 
activity of IFN-α as monotherapy in metastatic melanoma. Combination with CTLA-4 blockade 
may however alter this balance, downregulating the CTLA4 suppressive regulatory elements and 
possibly releasing inhibitory influences on activated CD25-expressing CD4 and CD8 effector 
cells, and thus, increase their antitumor response. Evidence supports the clinical activity and the 
immune modulation role of tremelimumab in unlocking the immune response by disrupting 
CTLA‐4, including T-cell cytokine enhancement (IL-2, IFN-γ) 54 and increased T-cell infiltration 
in responding tumors.55 Clinically, both IFN-α and tremelimumab have been demonstrated to 
have significant clinical activity in melanoma,43, 44, 56, 57 and where clinical activity appears to be 
associated with the induction of autoimmunity as a correlate of clinical benefits and as a sign of 
altered immunologic tolerance.19, 58-71 Immunologically, both have been demonstrated to up-
regulate the pro-inflammatory cytokine response (Th1 polarization) in patients with melanoma,46, 
54 and to be associated with increased T-cell and Dendritic cell infiltration in tumor in clinical 
responders.13, 55  
 
4.2 METHODS  
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Safety and efficacy of combination biotherapy of IFNα-2b and CTLA-4 blockade with 
tremelimumab in patients with inoperable AJCC stage III and stage IV melanoma  
 
4.2.1 Primary (1st) Objective:– To test the hypothesis that the combination of IFNα-2b and 
anti-CTLA-4 mAb would improve the response rate in patients with recurrent inoperable AJCC 
stage III and stage IV melanoma.  
 Patients underwent baseline imaging studies (MRI brain, and total body PET-CT (with or 
without brain). A restaging CT (or PET-CT or MRI if CT could not be done) was done every 12 
weeks for response assessment during therapy. Response Evaluation Criteria In Solid Tumors 
(RECIST) version 1.0 were utilized 72. Study size was based on my therapeutic target of 
achieving with acceptable toxicity a 20% or better rate of objective response, CR or PR by 
RECIST criteria, as compared to the 5% to 10% expected in patients eligible for study.  I also 
base my estimate of study size on an optimal two-stage design in which 16 patients were enrolled 
in stage 1, provided toxicity was acceptable.  Provided 2 or more responses occur among the first 
16 patients treated, then an additional 21 patients would be enrolled in stage 2 (N = 37 patients 
total).  A goal of 5 or more responses occurring by the end of stage 2 was set in order to consider 
the regimen to be potentially worthy of further investigation.  Characteristics of this two-stage 
design are as follows: α = 0.10 one-sided test of HA (π = 0.20) vs. H0 (π = 0.07), where the 
parameter π represents the proportion of patients who responded to treatment; power = 0.80; 
69% chance of stopping by the end of stage 1 if the underlying response rate is 7% or less. 
 
4.2.2 Secondary (2nd) Objectives:– To test the hypothesis that the combination therapy would 
improve the overall survival rate and the progression free survival (PFS) for these patients. 
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 Overall survival (OS) was measured from the initial date of treatment to the recorded date 
of death. Progression-free survival (PFS) was measured from the initial date of treatment to the 
date of documented progression by clinical or radiological evidence, or the date of death in the 
absence of documented progression. Median PFS in recent large phase III clinical trials has been 
estimated at 2.4 months 73-75. Although study size was planned in terms of our primary efficacy 
endpoint, objective response, we considered study power with respect to this important 
secondary endpoint. In addition, one-year survival rate was evaluated according to Korn et.al.20  
3rd Objective – To evaluate the toxicities and tolerance of this combination in this patient 
population.  
 Toxicity specific dose modification criteria were utilized for both tremelimumab 76 and 
IFN-α2b 77, 78. In addition, toxicity specific management algorithms/guidelines for both 
tremelimumab and IFN-α2b were used. Patients were monitored continuously for adverse events 
using the National Cancer Institute’s (NCI) Common Terminology Criteria for Adverse Events 
version 3 (CTCAE v.3). Although all patients were treated with a combined regimen, we 
attempted to attribute SAEs to either IFN-α2b or tremelimumab.   
 
4.3 RESULTS 
4.3.1   Patient Characteristics 
Thirty-seven patients (23 male, 14 female), age 28-76 (median 56) were enrolled between 
11/2006 and 3/2010. All had AJCC stage IV (9 M1a, 6 M1b, 22 M1c) and most had previously 
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received therapy (0-5 regimens). Two patients had prior treated brain metastases. Table 1 
summarizes the study population’s demographics and baseline patient characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.2 Treatment Details 
Seventy two courses of tremelimumab have been administered to date (average 
2/patient). Table 2 summarizes the treatment details and the reasons for discontinuation. 
Table 1. IFN-Treme. Patient Demographics and Baseline Disease Characteristics 
(N=37 patients) 
Variable  No. of Patients (%) 
Age, years                     
Median (Range) 
56 (28-76) 
Cutaneous/unknown primary  29 (78) 
Ocular   8 (22) 
 Gender                             
                                    Female  
                                    Male 
 
14 (38)  
23 (62) 
Performance Status           
0  
1  
 
18 (49) 
19 (51) 
Prior Therapy  22 (60) 
         # Prior Regimens (range) 1-5  
Prior Brain metastases 2 (5.4) 
 AJCC stage               
                                    M1a 
  
9 (24)  
                                    M1b  6 (16)  
                                    M1c  22 (60) 
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4.3.3  Efficacy 
At the end of stage I enrollment (N=16), the study met the interim analysis criterion of at 
least 2 objective responses by RECIST and, therefore, moved into stage II enrolment. 
 
4.3.3.1 Response (stages I and II)  
Response data are available for 35 patients. Best objective response rate (35 evaluable 
patients) is 26% (90% CI=0.14, 0.38) (4 CR and 5 PR lasting  6, 6, 12+, 14+, 18+, 20, 28+, 30, 
37+ months), including M1a (5 patients), M1b (2),  and M1c (3; including one uveal primary). 
Thirteen patients (37%) had SD (lasting 1.5 to 21 months). Disease control rate is 66% (90% 
CI=0.53, 0.79). For one additional patient the partial response status was not confirmed then had 
PD (per RECIST) after which the patient was rendered disease free (NED) surgically. This 
patient continues to be NED postoperatively at 16+ months. Another patient who had PD as best 
Table 2. IFN-Treme. Treatment Details  
Course No. pts treated 
(%) 
No. pts off study 
after treatment  
(%) 
PD as 
Reason for 
D/C  (%) 
Toxicity as 
Reason for 
D/C (%) 
Other* – 
Reason for 
D/C (%) 
1 37/37 (100) 20/37 (54) 12/20 (60)  4/20 (20) 4/20 (20) 
2 17/37 (46) 7/17 (41) 6/7 (86) 0 1/7 (14) 
3 10/37 (27) 2 2/2 (100) 0 0 
4 8/37 (22)     
* Poor performance status (1); Patient/MD decision to pursue surgery (2); second malignancy (1); 
early(1). PD: disease progression; D/C: discontinue treatment 
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response went on to receive 2 weeks of temozolomide and decitabine on a study and 
discontinued due to toxicities and transferred to hospice care. This patient presented in an NED 
status by PET-CT 15 months later with no other treatment for melanoma in the interim. Table 3 
summarizes the efficacy by tumor response and Table 4 summarizes the duration of responses  
and stable disease.  
 
 
I conducted a one tailed binomial test that the observed response rate (9/35 = 26%) was 
better than the comparison rate of 7%.  This test yields p = .0005 and thus we reject the null 
hypothesis and claim the therapy was significantly better than the assumed “uninteresting” rate 
of 7%. 
 
Table 3.  IFN-Treme. Efficacy Summary (stage I + II): Best Response (N=37) 
   No. Pts  
 
Duration  
(month)  
Primary: No. Pts (%) Classification: No. Pts 
(%) 
Cutaneous  Ocular  Unknown  M1a  M1b  M1c  
RR  
 
Overall 10  9/10 (90) 1/10 (10) 0 5/10 
(50) 
2/10 
(20) 
3/10 
(30) 
CR 4/10 
 
14+ – 30  3/4 (75) 1/4 (25) 0 1/4 
(25) 
1/4 
(25) 
2/4 
(50) 
PR* 6/10 
 
3 – 37+  6/6 (100) 0 0 4/6 
(67) 
1/6 
(17) 
1/6 
(17) 
SD  13 
 
1.5 – 21  7/13(54) 4/13 (31) 2/13 (15) 3/13 
(23) 
3/13 
(23) 
7/13 
(54) 
PD  11 
 
 8/11 (73) 3/11 (27) 0 1/11 
(9) 
1/11 
(9) 
9/11 
(82) 
No response 
data  
2 • 2 (1 cutaneous, M1c and 1unknown, M1c) unknown response 
 
*1 PR was not confirmed per RECIST, had PD and rendered surgically NED with no progression at 16+ months 
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Table 4. IFN-Treme. Durability of responses and stable disease (best radiologic response) 
Responders (N=10)   Stable Disease (N=13) 
Primary  Classification  Duration  
(Mon)  
Comment  Primary Classification Duration 
(Mon) 
1. Cutaneous  M1a 37+ PR  
surgical CR 
(NED) 
1.Cutaneous  M1c 1.5 
2.Unknown  M1a 4 
2.Cutaneous  M1c 30 CR 3.Cutaneous  M1c 9 
4. Ocular  M1c 4.5 
3.Ocular  M1c 28+ CR 
5.Ocular  M1c 13 
4. Cutaneous  M1c 20 PRPD  
Surgical 
NED 4+ 
months 
6.Cutaneous  M1a 2 
5.Cutaneous*  M1a 3 PR PD  
Surgical 
NED 16+ 
months 
7.Cutaneous  M1b 21 
8.Ocular  M1c 1.5 
6. Cutaneous  M1a 18+ CR  
9.Cutaneous  M1b 4 
7. Cutaneous  M1b 12+ PR (likely 
CR; residual 
4 mm lung 
nodule) 
10.Ocular  M1c 7 
8.Cutaneous  M1a 6 PR 
11. 
Cutaneous  
M1b 4.5 
9. Cutaneous  M1a 6 PR 
12. 
Cutaneous  
M1a 10.5 
10.Cutaneous  M1b 14+ CR 
13. 
Unknown  
M1c 4 (surgical 
NED 5 mo) 
*Unconfirmed PR (surgical NED). NED: no evidence of disease 
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4.3.3.2 Survival 
Median follow up time is 21 months (range 9 – 33 months) for patients at risk of 
progression and 22 months (range 15 – 44 months) for those who are still alive. Median PFS is 
6.4 months (95% CI = 3.3 – 13.1 months). The 6 months and 12 months PFS rate is 57% (95% 
CI = 00.39, 0.72) and 37% (95% CI = 0.21, 0.52) respectively. Figure 1 shows the Kaplan–
Meier plot of the probability of PFS. Median OS is 21 months (95% CI = 9.5 months, -). The 6 
months and 12 months OS rate is 84% (95% CI = 0.67, 0.92) and 62%; (95% CI = 0.45, 0.76) 
respectively. Figure 2 shows the Kaplan–Meier plot of the probability of OS. 
 
Figure 1. IFN-Treme. Kaplan – Meier plot of 
the probability of progression-free survival 
(N=37). The estimated median is 6.4 months  
(95% Confidence Interval = 3.3, 12.1) 
Figure 2. IFN-Treme. Kaplan – Meier plot of the  
probability of overall survival (N=37). The estimated 
median is 21 months (95% Confidence Interval = 9.5 
months, -) 
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We have recently started to explore the utility of OS and PFS as benchmarks for efficacy 
in phase 2 studies, rather than the traditional tumor response rate.20 Based on a meta-analysis of 
previously collected data from 42 cooperative group melanoma phase 2 trials conducted in the 
years 1975 to 2005, Korn et al have suggested the use of 1-year OS or 6-month PFS as 
benchmarks for future phase 2 studies.  The meta-analysis based on 1,278 patients provided an 
estimate of the 1-year OS rate (25.5%) and 1-year OS rates for 24 prognostic classes (ranging 
from 5.5% to 63.8%) defined by four significant prognostic factors that include PS, presence of 
visceral metastasis, sex and exclusion of patients with brain metastasis. The authors of the meta-
analysis acknowledged that future trials may have different survival rates than in the past 
because of patient mixes that differ in terms of prognostic variables. To address this, they 
suggested defining the null hypothesis target for a phase II trial based on the prognostic variables 
recorded in the trial and provided a table that contains the relevant information for a trial using a 
1-year OS rate as the endpoint. These predicted values are based on a logistic regression analysis 
with effects included for the four significant prognostic factors.  We utilized this model for our 
study, given the mix of patients with the same PS, incidence of visceral disease and gender 
distribution and given that our study did not allow patients with brain metastasis. The 
distribution of prognostic factors for 37 patients is shown in Figure 3 along with the observed 
and predicted 1 year survival rates for each prognostic category. The one year OS rate as 
predicted by the Korn model is 21% while the observed rate is 62% (95% CI = 46%, 78%); p 
<.0001.  
 
 
 
 19 
37 Patients Analyzed 
‐ 23 Alive at one year
‐14 Dead at one year
Observed 1 Year Survival Rate = 62%
95% Confidence Interval = 46% - 78%
One tailed hypothesis test: observed
rate better than predicted (21%) ‐> p  <.0001
Figure 3. IFN-Treme. One Year Survival Rate Observed vs Predicted (Korn 
Model)
As of 2/16/2011
One Year Survival Rate
Predicted by Korn
Model 
= 21%
Korn, et,al, JCO Feb 1, 2008
* Predicted rates assume the study was open to patients with brain metastasis
Gender PS Visceral
Disease
Total # Alive
@ 1 year
Observed
Rate
Predicted
Rate
Male 0 N 3 2 67% 35%
Male 0 Y 11 9 82% 22%
Male 1 N 3 3 100% 17%
Male 1 Y 6 2 33% 10%
Female 0 N 0 0 ‐‐‐ 49%
Female 0 Y 4 2 50% 33%
Female 1 N 3 2 76% 27%
Female 1 Y 7 3 43% 16%
 
 
4.3.4 Safety 
Table 5 summarizes AEs by severity that were considered possibly, probably or 
definitely related to the study regimen. Grade 3/4 toxicities include neutropenia (6 patients; 
17%), diarrhea/colitis (4; 11%), liver enzyme elevation (4; 11%), rash (4; 11%), fatigue (15; 
40%), anxiety/depression (5; 14%). Autoimmune toxicities due to tremelimumab were 
successfully managed with steroids. 
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Table 5. IFN-Treme. Adverse events considered possibly, probably or definitely related to the study regimen (CTCAE v.3) 
Type  All Grades  Grade 1  Grade 2  Grade 3  Grade 4  
 No. Patients  %  No. Pts.  %  No.  
Pts.  
%  No.  
Pts.  
%  No.  
Pts.  
%  
Immune mediated            
    Diarrhea/Colitis 21 57.0 7 19.0 10 27.0 3 8.0 1 2.7 
 Hyper/pothyroidism 2 5.4 0 0 2 5.4 0 0 0 0 
    Hypogonadism 1 2.7 0 0 1 2.7 0 0 0 0 
    Hepatitis-Increased     
AST/ALT/AP/GGT 
8 21.6 0 0 4 11.0 3 8.0 1 
(GGT) 
2.7 
    Skin rash 23 62.0 11 30.0 8 22.0 4 11.0 0 0 
Constitutional            
   Fatigue 37 100 17 46 5 13.5 15 40.5 0 0 
Gastrointestinal            
   Nausea 27 73.0 14 38.0 12 32.4 1 2.7 0 0 
   Vomiting 17 46.0 12 32.4 4 11.0 1 2.7 0 0 
Hematologic            
    Neutropenia 19 51.4 0 0 13 35.0 5 13.5 1 2.7 
Neuro-Psychiatric            
    Depression/Anxiety 9 24.3 4 11.0 1 2.7 4 11.0 0 0 
Renal            
    Increased 
Cr/dehydration 
2 5.4 1 2.7 0 0 1 2.7 0 0 
Respiratory            
    Bronchospasm 1 2.7 0 0 0 0 1 2.7 0 0 
Other            
Cardiac arrhythmia  
(atrial  fibrillation) 
1 2.7 0 0 0 0 1 2.7 0 0 
     Increased CPK 9 24.3 1 2.7 5 13.5 2 5.4 1 2.7 
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5.0 SECOND CHAPTER:  MULTI-EPITOPE VACCINATION WITH MART-
1 (26-35, 27L), GP100 (209-217, 210M), AND TYROSINASE (368-376, 370D) GIVEN 
WITH TLR-9 AGONIST AND GM-CSF 
 
 
 
5.1 TLR-9 ENGAGEMENT BY AGONIST PF-3512676 AND RATIONALE 
FOR COMBINATION WITH GM-CSF AS A POTENT IMMUNE ADJUVANT 
FOR A PROMISING MELANOMA TRIPLE PEPTIDE VACCINE AS A 
STRATEGY TO OVERCOME IMMUNE TOLERANCE IN ADVANCED 
MELANOMA 
TLR 9 agonists induce activation of DCs, resulting in increased cell surface expression of 
costimulatory molecules.79, 80 Activation of DCs also initiates a range of secondary effects, 
including secretion of cytokines/chemokines, activation of natural killer cells, and antigen 
presentation, resulting in induction of an adaptive immune response.79 PF-3512676 is a synthetic 
TLR9-activating oligodeoxynucleotide (ODN) that mimics unmethylated CpG single-stranded 
DNA, thus inducing DC maturation and enhancing antigen presentation.79, 81 This agent appears 
to have great potential to stimulate the immune response at the most fundamental level, thus 
overcoming tumor-induced immune suppression.82  
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PF-3512676 as an immune adjuvant: Tumor immunization strategies have been 
improved with the inclusion of CpG ODN as an adjuvant 83. It has also been shown that DCs 
produce high amounts of IL-12 following both stimulation with CpG ODN (through TLR9) and 
CD40 Ligand (provided endogenously by activated T-helper cells).84 PF-3512676 has been used 
in a series of human phase I studies given in association with HBs antigen, and shown to exhibit 
a strong adjuvant effect.85, 86 In addition, PF-3512676 enhanced the number of antigen-specific T 
cells induced by vaccination with Melan-A peptide vaccination plus incomplete Freund’s 
adjuvant ~10-fold.87  
GM-CSF locally in-ISA oil-adjuvant with tumor vaccines: When GM-CSF is 
administered locally with tumor vaccines it has been found to have beneficial effects on vaccine 
immune responses believed to be due to its effects on dendritic cells 88-91. GM-CSF incorporated 
with peptide in adjuvant was shown to be the single most effective cytokine for enhancing both 
cellular and humoral immunity to two previously characterized HIV-1 MN vaccine constructs. 
GM-CSF synergized with IL-12 for CTL induction in BALB/c mice concomitant with 
suppression of Th2 cytokines IL-4 and IL-10 89. Slingluff et al have observed in several human 
trials T cell responses to multiple peptides when administered in an emulsion of GMCSF-in-
adjuvant and have found that T cell responses in this cytokine-in-adjuvant combination were 
markedly more prevalent and higher in magnitude than when the same peptides were 
administered on dendritic cells 92, 93. In a phase II trial, stage IV melanoma patients underwent 
vaccination with (a) 4 melanoma peptides and tetanus peptide pulsed on autologous dendritic 
cells or (b) 4 melanoma peptides and tetanus peptide administered in Montanide ISA-51 plus 
GMCSF. Evaluation of the CTL response was assessed by IFN-γ ELISPOT assay in peripheral 
blood lymphocytes and in a lymph node draining a vaccine site (sentinel immunized node, SIN) 
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harvested after 3 immunizations. ELIspot assays showed substantially higher and more frequent 
CTL responses in the second arm, with peptides given in adjuvant plus GMCSF, than in the first 
arm, with peptides pulsed on dendritic cells 93.   The E4697 phase III trial evaluated systemic 
GM-CSF (as opposed to local administration of GM-CSF as done in this proposal) with or 
without peptide vaccination (utilizing tyrosinase: 368-376 (370D), Gp100: 209-217 (210M), 
MART-1: 27-35) peptides) as adjuvant therapy for in HLA-A2+ patients  with advanced 
melanoma. No significant overall survival benefit for systemic GM-CSF either administered 
alone, or as administered in conjunction with the triple peptide vaccine adjuvant in this study, 
again underscoring the importance of altering the application of GM-CSF as peptide vaccine 
adjuvant from the systemic route to the local in-oil adjuvant approach.     
 The combination of CPG ODN and GM-CSF:  Data from preclinical studies 
supports the combination of CPG ODN and GM-CSF as immune adjuvants enhancing antigen-
specific immune response compared to immunostimulatory strategies employing either agent 
alone.91, 92 This is not surprising. In fact, when GM-CSF is administered locally with tumor 
vaccines it has been found to have beneficial effects on vaccine immune responses believed to be 
due to its effects on dendritic cells 69, 88, 94, 95, including evidence that GM-CSF attracts DCs to 
the site of injection.96, 97 In our approach, this will be coupled with the impact of the TLR9 
agonist on enhancing plasmacytoid dendritic cell (pDC) maturation, increasing their expression 
MHC class I and II molecules and costimulatory molecules, and promoting Th1-type immune 
responses.98, 99  
Vaccination with multi-epitope peptide vaccine containing MART-1 (27-35), gp100 
(209-217, 210M), and tyrosinase (368-276, 370D) peptides: ECOG 1696 is a completed phase 
II trial of multi-epitope peptide vaccination for metastatic melanoma with or without IFNα2b or 
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GM-CSF as an immune adjuvant, in a 2x2 factorial design. This study accrued 120 patients, and 
complete immunological data is available for 75 who had undergone 3 months of immune 
assessment. Immunity to CD8 epitopes of one or more of 3 lineage antigens inducible in 35% of 
patients with measurable metastatic melanoma was demonstrated. ELIspot assay responses, 
defined by the doubling of pretreatment T-cell precursor frequencies, were found to be 
associated with longer median survival but not with progression free survival. The influence of 
GM-CSF and IFNα2b, both given systemically, on the vaccine’s immunological and antitumor 
responses did not reach statistical significance.100 Therefore, our vaccine study was aimed at 
improving immunization against MART-1, gp100, and tyrosinase peptides by employing a 
potent immunological adjuvant approach combining PF-3512676 and GM-CSF, given with the 
peptides locally in oil-adjuvant. 
 
5.2  METHODS 
Safety and immunogenicity of vaccination with multi-epitope peptide vaccine containing 
MART-1 (26-35, 27L),  gp100 (209-217, 210M), and tyrosinase (368-376, 370D) peptides 
given in-oil-adjuvant with the combination of TLR-9 agonist PF-3512676 and GM-CSF for 
HLA-A2+ patients with inoperable stage III or stage IV melanoma  
 
Using continuous monitoring of safety along with a two-stage design for immunological 
efficacy, up to 20 immune-response evaluable patients were enrolled on study. Vaccination was 
given on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year). 
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5.2.1 Primary (1st) Objective: - To test the hypothesis that the combination PF-3512676 and 
GM-CSF is an efficient vaccine adjuvant that in combination will induce significantly enhanced 
antigen-specific CD8+ T cell responses as measured by ELIspot assay. 
From study E1696, an estimated 30% of patients treated with vaccine alone were 
expected to show an immunologic response, i.e., one in which the number of reactive CD8+ T 
cells against any of the HLA-A2-restricted peptides MART-1, gp100, and tyrosinase (measured 
by ELIspot assays) doubles (as compared to baseline) after 4 vaccinations, and for which the 
increment is at least 10 spots. My immunologic objective was to increase this response rate to 
60% or more by our investigational vaccine.  The ELIspot assay for quantitating peptide-reactive 
CD8+ T cells was developed and refined for clinical applications 101, 102. The frequency of CD8+ 
T cells freshly isolated from peripheral blood were tested for immunoreactivity against HLA-A2-
restricted peptides MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 
370D).  I therefore planned to use a two-stage design for immunologic response. Provided 
toxicity is acceptable, 10 patients were enrolled in stage 1.  Provided that 4 or more “responses” 
occurred, an additional 10 patients would be enrolled in stage 2. A goal of 9 or more responses 
occurring by the end of stage 2 (N=20 total) was set in order to consider our vaccination regimen 
to be potentially worthy of further study.  (Design characteristics: α = 0.098 one-sided test; 
power = 91%; 65% chance of stopping by the end of stage 1 if the underlying immunologic 
response rate is only 30%).   
 
5.2.2 Secondary (2nd) Objectives: - To evaluate the safety of this regimen. (3rd Objective) - 
To evaluate the tumor response by RECIST criteria and correlate immunologic response with 
clinical response data. 
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5.3 RESULTS 
5.3.1 Patient Characteristics 
Twenty-two patients (11 male, 11 female), age 48-81 (median 66) were enrolled between 
01/2009 and 12/2010. All had AJCC stage IV (5M1a, 6M1b, 11M1c) and most had previously 
received therapy (0-3 regimens). Eight patients had prior treated brain metastases. Table 6 
summarizes the study population’s demographics and baseline patient characteristics.              
 
 
 
 
 
Table 6. Vaccine. Patient Demographics and Baseline Disease Characteristics (N=22)  
Variable  No. of Patients (%) 
Age, years                     
Median (Range) 
66 (48 - 81) 
Cutaneous 
Unknown primary 
Mucosal  
17 (77) 
4 (18) 
1 (5) 
 Gender                             
                                    Female  
                                    Male 
 
11 (50) 
11 (50) 
Performance Status           
0  
1  
 
3 (14) 
19 (86)  
Prior Therapy   
         # Prior Regimens (range) 0 - 3 
Prior Brain metastases 8 (36) 
 AJCC stage               
                                    M1a 
 
5 (23) 
                                    M1b  6 (27) 
                                    M1c  11(50) 
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5.3.2 Treatment Details 
Seventy eight cycles (156 vaccinations) have been administered as of 03/2011 (average 
3.5/patient). Table 7 summarizes the treatment details and the reasons for discontinuation.  
 
Table 7. Vaccine. Treatment Details (N= 21* evaluable patients) 
Cycles 
completed 
No. pts 
treated (%) 
No. pts off 
study after 
treatment (%) 
PD as 
Reason for 
D/C (%) 
Toxicity as 
Reason for 
D/C (%) 
1 21/21 (100) 0 NA NA 
2 21/21 (100) 11/21 (52) 11/11 (100) 0 
3 10/21 (48) 1/21 (5) 1/1 (100) 0 
4 9/21 (43) 4/21 (19) 4/4 (100) 0 
≥5 
(5-12) 
5/21(24) 4/21(19) 4/4/(100) 0 
*One additional patient considered non-evaluable received one vaccination 
 
 
5.3.3 Efficacy 
A total of 22 patients were enrolled on this study. One who received one vaccination and 
had a bleeding brain tumor at baseline despite adequate radiotherapeutic management was 
considered non-evaluable for efficacy. Another patient had no post-vaccination lymphocytes 
collected for ELIspot. At the end of stage I enrollment of 10 immune response evaluable (have 
baseline and post-vaccination blood specimens for ELIspot testing) patients, the study met the 
interim analysis criterion of at least 4 positive immune responses by ELIspot and, therefore, 
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moved into stage II enrolment of 10 additional patients (Total N=21 evaluable for clinical 
efficacy and 20 evaluable for immunological efficacy). 
 
5.3.3.1 Immunological Efficacy (Stages I and II)  
Twenty patients were evaluable for immunological efficacy. Positive ELIspot is defined 
as the number of reactive CD8+ T cells against any of the HLA A2-restricted peptides MART-1, 
gp100, and tyrosinase that doubles (as compared to baseline) after 4 vaccinations, and for which 
the increment is at least 10 spots. There were 8/20 patients with ELIspot at day 50 and 5 (out of 
10 patients with day 90 specimens) ELIspot positive at day 90. One patient was negative at day 
50 and positive at day 90. Therefore, there were a total of 9/20 patients with positive ELIspot at 
day 50 and/or day 90. Among the ELIspot positive patients, 6/9 had SD or PR as the best anti-
tumor response and 3 had PD. Table 8 summarizes the immunologic response data.  
The cytotoxic T cell response rate to each peptide is similar at day 50 (N=20 patients), 
but are different at day 90 (N=10 patients). However, this analysis is limited by the small sample 
size. Table 9 summarizes the peptide specific response rate by IFN-γ ELIspot at day 50 and day 
90. The change in ELIspot CD8+ T cell frequency was measured by the ratio of post versus pre 
treatment value of ELIspot number of CD8+ T cells against each of the specific antigens. 
Wilcoxon signed ranked test was used to test whether this ratio is equal to 1. These data are 
presented in Table 10. 
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Table 8. Vaccine. Summary of tumor response data (RECIST): Best Response (N=22) 
and immunologic response (ELIspot) at day 50 and day 90 post-vaccination (N=20) 
 
Primary Stage 
Best 
Response 
(RECIST) 
Duration 
of Resp. 
(Months) 
History of 
brain 
metastases 
Site of 
progression 
 
ELIspot* 
Day 
50 
Day 
90 
1.Unknown M1a PD 0 yes brain, LN n NE 
2.Cutaneous M1b SD 4 0 LN, lung n n 
3.Cutaneous M1c PD 0 yes subQ, LN NE NE 
4.Cutaneous M1a SD 7 0 LN p p 
5.Cutaneous M1c PR 2 0 liver n p 
6.Cutaneous M1b PD 0 0 lung p NE 
7.Cutaneous M1b SD 2 0 lung n n 
8.Cutaneous M1b PD 0 0 lung p NE 
 9.Cutaneous   NE  NE  NE yes  NE NE NE 
10.Unknown M1c PD 0 0 LN, subQ n NE 
11.Cutaneous M1c SD 4 yes brain p n 
12.Unknown M1c SD 2 yes brain, lung n n 
13.Unknown M1c SD 6 yes brain p p 
14.Cutaneous M1a PD 0 0 subQ n NE 
15.Cutaneous M1c PD 0 yes brain, bone, liver, lung 
n NE 
16.Cutaneous M1c PD 0 yes brain p NE 
17.Cutaneous M1c PD 0 0 liver, lung, muscle, subQ 
n NE 
18.Cutaneous M1a PD 0 0 liver, LN, subQ 
n NE 
19.Cutaneous M1a PD 0 0 LN, subQ n NE 
20.Cutaneous M1c SD 2 0 LN p p 
21.Mucosal M1b SD 2 0 Lung p p 
22.Cutaneous M1b PR 4+ 0 NA n n 
NE: non-evaluable; LN: lymph node; subQ: subcutaneous; NA: non-applicable; p=positive; n=negative 
*Twenty patients had day 50 samples for ELIspot testing and only 10 had day 90 samples 
 
Table 9. Vaccine. Peptide specific response rate by IFN-γ ELIspot at day 50 
(N=20) and day 90 (N=10) 
 Response rate (90% CI) 
 DAY 50 DAY 90 
T2+CD8+Mart 27-35 0.32 (0.15, 0.53) 0.1 0 (0.005, 0.39) 
T2+CD8+Gp100 209-217 0.25 (0.10, 0.46) 0.50  (0.22, 0.78) 
T2+CD8+Tyr368-376D 0.28 (0.12, 0.50) 0.20 (0.037, 0.51) 
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Table 10. Vaccine. The change in ELIspot CD8+ T cell frequency as measured by the ratio of 
post versus pre treatment value of ELIspot number of CD8+ T cells against each of the specific 
antigens. 
 Day 50 Day90 
 Median 
(range) 
p-value Median 
(range) 
p-value 
T2+CD8+Mart 27-35 1.5 (0, inf) 0.02 1.4 (0.4, 3.2) 0.11 
T2+CD8+Gp100 209-
217 
1.3(0, Inf) 0.05 1.7 (0.3, 18.5) 0.06 
T2+CD8+Tyr368-376D 1.3 (0, 4.7) 0.03 1.5 (0.4, 3.9) 0.06 
 
 
5.3.3.2 Response  
Response data are available for 21 patients. Two patients (M1b, M1c) had PR and 8 
(4M1c, 3M1b, 1M1a) had SD lasting 2-7 months. Among 7 evaluable patients with history of 
treated brain metastases, 6 had disease progression in the brain.    
 
5.3.3.3 Survival 
 One patient with ongoing SD continues on treatment. All other patients have 
progressed and among these only 10 are still alive with a median follow up time of 7.39 months 
(range 3.22 to 20.47 months).  Among the first 11 patients enrolled on the study who have 
reached at least 1 year of follow up from first vaccination, 8 were alive at one year.  
 
Median PFS is 1.87 months (90% CI=1.84, 3.68). Figure 4 shows the Kaplan–Meier plot of the 
probability of PFS. Median OS is 13.4 months (90% CI=11.3, Inf). Figure 5 shows the Kaplan–
Meier plot of the probability of OS. 
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5.3.4 Safety 
Table 11 summarizes AEs by severity that were considered possibly, probably or definitely 
related to the study regimen. No regimen-related grade 3/4/5 toxicities were observed. 
 
 
 
 
 
Figure 4. Vaccine. Kaplan – Meier plot of  
the probability of progression-free survival 
(N=21). The estimated median is 1.87 
months (90% CI=1.84, 3.68) 
Figure 5. Vaccine. Kaplan – Meier plot of 
the probability of overall survival (N=21).  
The estimated median is 13.4 months (90% 
CI=11.3, Inf) 
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Table 11.  Vaccine. Adverse events considered possibly, probably or definitely related to the study regimen 
presented by worst grade (CTCAE v.3) (N=22 patients) 
Type  All Grades  Grade 1  Grade 2  Grade 3/4  
 No. 
Patients  
%  No. Pts.  %  No.  
Pts.  
%  No.  
Pts.  
%  
Constitutional          
   Allergic rhinitis 3 14 2 9 1 5 0 0 
   Fatigue 9 41 7 32 2 9 0 0 
   Fever 4 18 4 18 0 0 0 0 
   Insomnia 3 14 2 9 1 5 0 0 
   Rigors/chills 3 14 3 14 0 0 0 0 
  Sweating/diaphoresis 1 5 1 5 0 0 0 0 
   Weight loss 1 5 1 5 0 0 0 0 
   Limb edema 2 9 1 5 1 5 0 0 
Dermatologic/Skin         
Injection site reaction  15 68 15 68 0 0 0 0 
Pruritus/itching 5 23 4 18 1 5 0 0 
Rash 2 9 1 5 1 5 0 0 
Gastrointestinal          
   Anorexia 2 9 1 5 1 5 0 0 
   Diarrhea 2 9 2 9 0 0 0 0 
   Nausea 9 41 8 36 1 5 0 0 
   Taste alteration 1 5 0 0 1 5 0 0 
   Vomiting 7 32 1 5 5 23 0 0 
Infection         
   Mucosal  1 5 0 0 1 5 0 0 
   Skin  1 5 0 0 1 5 0 0 
Neuro-Psychiatric          
    Psychosis 1 5 0 0 1 5 0 0 
Respiratory          
    Cough 2 9 2 9 0 0 0 0 
    Dyspnea 1 5 1 5 0 0 0 0 
Other          
Hypertension  1 5 1 5 0 0 0 0 
    Hypotension 1 5 1 5 0 0 0 0 
    Headache 4 18 1 5 3 14 0 0 
   Pain    (muscle/extremity) 6 27 6 27 0 0 0 0 
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6.0 THIRD CHAPTER: BIOMARKERS 
 
 
 
6.1 CANDIDATE BIOMARKERS OF PROGNOSTIC AND/OR PREDICTIVE 
VALUE TESTED IN CORRELATION WITH THE 2 CLINICAL TRIALS AS 
MARKERS OF CLINICAL BENEFIT AND REVERSAL OF IMMUNE 
TOLERANCE (1) NON-ANTIGEN SPECIFIC COMBINATION 
IMMUNOTHERAPY WITH TREMELIMUMAB AND IFN-Α AND (2) ANTIGEN-
SPECIFIC TRIPLE PEPTIDE VACCINATION IN-OIL ADJUVANT WITH PF-
3512676 AND GM-CSF 
 
6.1.1 The induction of autoimmunity is associated with immunotherapeutic benefits and 
has a potentially significant prognostic value and may lead to future predictive biomarkers 
 
Paraneoplastic depigmentation among patients with melanoma has been reported to be a sign of 
favorable prognosis.103-105 Recent studies of immunotherapy for melanoma including high-dose 
IL-2 and anti-CTLA4 blocking antibodies have suggested a correlation of antitumor effects and 
autoimmune phenomena.19, 59-70, 106 Recently, a study testing a modified adjuvant IFN-α regimen 
(HeCOG 13A/97) reported a strong correlation of prolonged relapse-free and overall survival 
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with prospectively assessed autoimmune phenomena and/or the appearance of auto-antibodies in 
the serum.58  We, at the University of Pittsburgh and ECOG have had similar findings in our 
evaluation of sera from patients treated in the E2696 and E1694 adjuvant melanoma IFN-α 
trials.106 These observations support the hypothesis that the prevention of melanoma relapse and 
mortality with IFN-α is associated with immunomodulation that may increase resistance to 
melanoma. Therefore, the evaluation of induced autoimmunity in the context of our studies is 
reasonable as a potential surrogate of successful reversal of immune tolerance. Future studies of 
autoimmunity and its genetic determinants may help identify patients most likely to benefit from 
immunotherapies associated with autoimmunity.  
 
6.1.2 C-reactive protein (CRP) is an ideal candidate as a baseline predictive biomarker of 
therapeutic benefit and the capacity to overcome immune tolerance 
  
Data supports a role for high serum CRP as a poor prognostic maker and as a marker of immune 
tolerance in advanced melanoma.107 For first detection of melanoma stage IV disease, serum 
CRP has been shown to be potentially superior to conventional LDH measurement.108 As 
interesting is a potential role for CRP in mediating immune tolerance. CRP is synthesized by 
hepatocytes in response to interleukin-6 (IL-6) during inflammation in concentrations that 
oscillate between nontolerogenic and tolerogenic levels and where there is a physiological role of 
“ectopic” thymic expression in tolerance induction to CRP (and other acute-phase proteins) and 
possibly other inducible self-antigens.109, 110 CRP binds to phosphocholine (PC) and related 
molecules on microorganisms and plays an important role in host defense. However, a more 
important role may be the binding of CRP to PC in damaged membranes. CRP increases 
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clearance of apoptotic cells, binds to nuclear antigens and by masking autoantigens from the 
immune system or enhancing their clearance, CRP may prevent autoimmunity.109 Interestingly, a 
study utilizing a human hepatoma cell line showed that IFN-α inhibits CRP promoter activity 
and CRP secretion.111 Our ability to demonstrate a significant association between baseline CRP 
level and therapeutic benefit would first, provide a potential baseline predictive biomarker. 
Second, it may demonstrate the impact of IFN-α on reversing immune tolerance mediated by 
CRP if patients with higher baseline CRP are shown to benefit from the tremelimumab-HDI 
combination. This may open the way towrads future research focusing upon CRP as a potential 
mediator of tumor immune tolerance and possible inhibition as a component of an 
immunotherapeutic strategy.   
 
6.1.3 Absolute lymphocyte count (ALC) is another ideal candidate as a baseline predictive 
biomarker of therapeutic benefit and the capacity to overcome immune tolerance 
 
A lower total or absolute lymphocyte count (ALC) has been reported as a marker of immune 
suppression, increased risk of infection and poor prognosis in patients with HIV, tuberculosis 
and other infections.112, 113 Studies have shown that lymphopenia is commonly observed in 
patients with advanced cancers and correlated to poor prognosis in terms of overall and 
progression-free survival in patients with different cancer types, including breast cancer, 
sarcoma, lymphoma and colorectal cancer. 114-118 In patients with melanoma, a pooled analysis of 
3 studies testing ipilimumab anti-CLA4 blockade in metastatic melanoma, higher peripheral 
blood ALC after ipilimumab were significantly associated with clinical activity.119-121 Similarly, 
in another analysis of 51 evaluable patients who received ipilimumab at a single institution, ALC 
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also correlated with clinical benefit. Patients with an ALC ≥1000/uL after 2 ipilimumab doses 
(Week 7) had a significantly improved clinical benefit rate and median OS than those with ALC 
<1000/uL (51% vs 0%; 11.9 months vs 1.4 months).122 Therefore, the evaluation of baseline 
ALC in the context of our studies is reasonable as a potential predictive biomarker of clinical 
benefit.  
  
6.1.4 Monitoring the impact of our regimens on circulating T regulatory cells (T-reg) and 
myeloid derived suppressor cells (MDSC) may allow a better understanding of the 
differential clinical outcome  
 
Regulatory T cells mediate homeostatic peripheral tolerance by suppressing autoreactive T cells. 
However, tumors appear to benefit from an immunosuppressive role mediated by Tregs that 
suppress tumor-specific T cell immunity and contribute to growth of human tumors.123 Tregs 
have been shown to accumulate in human tumors and the peripheral circulation of patients with 
cancer and contribute to down-regulation of immune activity of effector T cells and suppression 
in the tumor microenvironment by several mechanisms.123, 124 In parallel, myeloid-derived 
suppressor cells (MDSCs) have been implicated in the induction of CD8(+) T cell tolerance in 
tumor-bearing hosts. They are increased in frequency in the peripheral circulation and tumors of 
nearly all cancer patients and have a remarkable ability to suppress T-cell responses.125 We 
hypothesize that superior immunotherapeutic clinical activity would be associated with more 
effective downregulation of the host suppressor cellular immune response. 
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6.1.5 Other candidate biomarkers for testing in the context of these 2 trials  
 
A variety of other non-specific melanoma biomarkers, cytokines and chemokines that have 
potential disease prognostic or therapeutic predictive value and are associated with the 
phenomena of reversal of immune tolerance are good candidates to be pursued in this analysis 
(reviewed by Tarhini, et. al.  Diagnostic and Prognostic Biomarkers and Therapeutic 
Targets in Melanoma. Springer Science/Humana Press. 2010). Please see section IV.B. In 
addition, tumor antigen specific T cell responses have been pursued (data pending).  
 
Antigen-specific T-cell immune response is associated with improved survival in 
advanced melanoma patients treated with peptide vaccination and would be a reliable 
biomarker of a potentially improved immunization strategy:  Vaccination with multi-epitope 
peptide vaccine containing HLA-A2-restricted MART-1 (27-35), gp100 (209-217, 210M), and 
tyrosinase (368-276, 370D) peptides has been employed in several clinical trials with consistent 
evidence that the vaccination is well tolerated and could be associated with immunological and 
clinical responses in melanoma 93 In E1696, ELIspot assay responses defined by doubling of 
pretreatment antigen-specific T cell precursor frequencies was found to be associated with longer 
median survival (21.3 versus 10.7 months; p=0.001), but not progression free survival. The 
influence of GM-CSF and IFNα2b, both given systemically (a point of distinction from our study 
where GM-CSF is given locally in-ISA oil-adjuvant with the peptides), upon the vaccine 
immunological and antitumor responses did not reach statistical significance 6. 
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CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in 
metastatic melanoma patients with clinical benefit: Fifteen metastatic melanoma patients 
treated with ipilimumab anti-CTLA-4 therapy were selected on the basis of availability of 
suitable specimens for immunologic monitoring, and eight of these showed evidence of clinical 
benefit. Five of the eight patients with evidence of clinical benefit had NY-ESO-1 antibody, 
whereas none of seven clinical non-responders was seropositive for NY-ESO-1. All five NY-
ESO-1 seropositive patients had clearly detectable CD4+ and CD8+ T cells against NY-ESO-1 
following treatment with ipilimumab. One NY-ESO-1 seronegative clinical responder also had a 
NY-ESO-1 CD4+ and CD8+ T cell response, possibly related to prior vaccination with NY-ESO-
1. Among five clinical non-responders analyzed, only one had a NY-ESO-1 CD4+ T cell 
response and this patient did not have detectable anti-NY-ESO-1 antibody. Overall, NY-ESO-1-
specific T cell responses increased in frequency and functionality during anti-CTLA-4 treatment, 
revealing a polyfunctional response pattern of IFN-γ, MIP-1β and TNF-α. It was therefore 
suggested that CTLA-4 blockade enhanced NY-ESO-1 antigen-specific B cell and T cell 
immune responses in patients with durable objective clinical responses and stable disease.126 
 
6.2 METHODS 
Candidate biomarkers of prognostic and/or therapeutic predictive value tested in 
correlation with immune tolerance and clinical benefits in both studies  
 
For the purpose of biomarker studies conducted within the IFNα-2b and anti-CTLA-4 clinical 
trial, blood samples were collected at baseline (before any treatment), during therapy and at 
progression. 
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6.2.1 First Objective: To test the hypothesis that the development of autoimmunity in 
melanoma patients during therapy is associated with clinical benefit (CR, PR, or SD).  
Patient serum samples were tested (baseline, during treatment and at progression) for the 
presence of the following autoantibodies using ELISA 127: Antinuclear antibody (ANA) Screen, 
Thyroid Stimulating Immunoglobulin (TSI), Antithyroglobulin antibody (ATGAB),  
Antithyroperoxidase Antibody (ATPOAB), Antimicrosomal antibody (negative <1:100 titer),  
Anticardiolipin (TOTAL: IgA + IgM + IgG).   
Definition of “induced autoimmunity”: Induced autoimmunity (present/absent) was defined by at 
least one of the following: 
• the existence of antibody (during treatment) above threshold to any one of 6 different 
antigens 
• the existence of immune-related adverse events (irAEs) during treatment (CTCAE v.3 
grade 2 or higher except for isolated hypopigmentation due to the fact that the vaccine 
targets melanosomal lineage antigens and potentially may confound our analysis). 
The associations between induced autoimmunity (present/absent) and clinical benefit (CR, PR, 
or SD versus PD) were tested using Fisher's Exact Test.  
 
6.2.2 Second Objective: Test the hypothesis that baseline C-reactive protein (CRP), absolute 
lymphocyte counts (ALC), vascular endothelial growth factor (VEGF), interleukin-6 (IL6), and 
other candidate biomarkers are predictive for therapeutic benefit. 
These biomarkers were measured in serum utilizing baseline serum samples and were 
tested by ELISA.127 Clinical benefit was defined as stable disease (SD) or response (PR or CR) 
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versus progression (PD) by RECIST criteria. The association between a certain biomarker 
(high/low) and clinical benefit (CR, PR, or SD versus PD) were tested using Fisher's Exact Test.  
 
6.2.3 Third Objective: Test the hypothesis that superior clinical activity will be associated with 
more significant modulation/downregulation of the host suppressor cellular immune response.  
Multicolor flow cytometry was used to compare cellular marker expression on peripheral 
blood mononuclear cells (PBMCs) before and after treatment, focusing on circulating T-
regulatory cells and myeloid derived suppressor cells. T-regs were defined as cells expressing (1) 
CD4+CD25hi+FoxP3+ or (2) CD4+CD25hi+CD39+ activated T cells (CD3+CD4+CD25+).128 
MDSC were defined as cells expressing (1) Lin1-/HLA-DR-/CD33+/CD11b+ lymphoid type 
MDSC, (2) Lin1-/HLA-DR-/CD33+/CD11b+ monocytic type MDSC or (3) HLA-DR+ 
low/CD14+ monocytic type MDSC.129, 130 Within-patient changes in T-regs and MDSCs from 
baseline to day 29 (IFN/treme) or day 50 (vaccine) and from baseline to day 85 (IFN/treme) or 
day 90 (vaccine) were be tested by Wilcoxon signed-rank test. Within-patient changes in T-regs 
and MDSCs were also compared between the patients with CR/PR/SD tumor response (RECIST) 
and those with PD response, by using the two-sample Wilcoxon rank-sum test. 
 
6.3 RESULTS 
 
6.3.1 Safety and efficacy of combination biotherapy IFNα-2b and CTLA-4 blockade with 
tremelimumab in patients with inoperable AJCC stage III and stage IV melanoma 
6.3.1.1 Induced Autoimmunity 
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There is significant association between autoimmunity and clinical benefit (CR/PR/SD 
versus PD; P= 0.0059) by Fisher's Exact Test. Figure 6. 
 
Figure 6. IFN-Treme. This figure illustrates the distribution of patients with therapy-
induced autoimmunity by clinical benefit (CR/PR/SD versus PD).   
 
Auto
immu
nity 
Clinical
Benefit
CR/PR/
SD PD
Tot
al
No 3 7 10
Yes 19 4 23
Total 22 11 33
 
 
 
6.3.1.2 CRP 
There is significant association between baseline CRP (<=2.7ULN versus >2.7ULN) and 
clinical benefit (p= 0.0494 by Fisher's exact test). The probability of survival is also significantly 
different (p= 0.0032 by log-rank test) in favor of low CRP. Figure 7.  
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Figure 7. IFN-Treme. This figure illustrates the distribution of C-reactive protein by clinical benefit 
(CR/PR/SD versus PD) and the probability of survival (CRP; <=2.7ULN versus >2.7ULN).  
 
CRP Clinical Benefit
CR/PR/SD PD Total
<=2.7ULN 18 5 23
>2.7ULN 4 6 10
Total 22 11 33
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6.3.1.3 ALC 
ALC at baseline is significantly different by response (CR/PR versus SD/PD; p= 0.0183) 
and by clinical benefit (CR/PR/SD versus PD; p=0.0255) by Wilcoxon two-sample test. Figure8. 
 
Figure 8. IFN-Treme. This figure illustrates the distribution of the baseline absolute lymphocyte 
count (ALC) by response (CR/PR versus SD/PD) and by clinical benefit (CR/PR/SD versus PD).   
 
 
 
 
 
6.3.1.4 VEGF and IL-6 
Figure 9 illustrates the distribution of baseline VEGF and IL-6 by clinical benefit 
(CR/PR/SD versus PD).  
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Figure 9. IFN-Treme. This figure illustrates the distribution of baseline VEGF and IL-6 by clinical benefit 
(CR/PR/SD versus PD).   
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6.3.1.5 Multicolor flow cytometry comparing cell surface marker expression on PBMCs 
before and after treatment to monitor T-regulatory cells (T-reg) and myeloid-derived 
suppressor cells (MDSC) in the blood at baseline and following treatment  
 
T-regs were defined as cells expressing (1) CD4+CD25hi+FoxP3+ or (2) 
CD4+CD25hi+CD39+ 128. MDSC were defined as cells expressing (1) Lin1-/HLA-DR-
/CD33+/CD11b+ (lymphoid type MDSC), (2) Lin1-/HLA-DR-/CD33+/CD11b+ (monocytic 
type MDSC) or (3) HLA-DR+ low/CD14+ (monocytic type MDSC)129, 130. Change in T-reg and 
MDSC was compared between baseline, Day 29 (completion of the induction phase of IFN-α) 
and day 85 (completion of one course of combination of tremelimumab and IFN-α). Table 12 
and Figure 10 summarize the flow cytometry data comparing cell surface marker expression on 
PBMCs before and after treatment. There was significant increase in the percentage of 
CD4+CD25hi+ CD39+  T-reg at D85 (p=0.018) and less significantly at D29 (p=0.09) compared 
to baseline, as illustrated in Figure 11.   
 
 
 
 
 
 
 
 
 46 
 
 
 
 
 
 
 
 
 
 
 
Table 12. IFN-Treme. Multicolor flow cytometry comparing cell surface marker expression on 
PBMCs before and after treatment to monitor T-regulatory cells (T-reg) and myeloid-derived 
suppressor cells (MDSC) in the blood at baseline and following treatment (Day 29 and Day 85) in 
patients treated with tremelimumab and IFN-α. 
 
Change 
at D29 
Std 
Dev  
P-
value 
 
Change 
at D85 
Std 
Dev 
P-
value 
 
D 29: 
CR/PR  
vs.  
SD/PD 
D 85: 
CR/PR 
vs. 
SD/PD 
T-Regs       P-value P-value 
CD4+ % 4.3 8.7 0.003 2.2 11.85 0.283 0.226 0.164 
CD4+CD25+ % -1.0 3.0 0.065 -0.6 4.59 0.292 0.771 0.948 
CD4+/CD25hi+ 
% -0.4 1.3 0.186 0.0 1.42 0.912 0.803 0.727 
CD4+CD25hi+ 
CD39+ % 3.6 23.4 0.092 7.7 17.89 0.018 0.088 0.220 
CD4+CD25hi+ 
Foxp3+ % 1.9 8.7 0.190 2.1 6.58 0.108 0.562 0.695 
MDSC         
% lymphoid type  
Lin1-/HLA-DR-
/CD33+/CD11b+ -1.1 6.8 0.055 -2.0 5.97 0.072 0.131 0.048 
% monocyte type  
Lin1-/HLA-DR-
/CD33+/CD11b+ -6.1 20.6 0.040 1.5 26.07 0.873 0.771 0.679 
% monocyte type 
HLA-DR+ 
low/CD14+ -21.5 28.2 
<.000
1 -14.3 21.11 0.001 0.041 0.529 
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Figure 10. IFN-Treme. This forest plot presents graphically the multicolor flow cytometry data 
summarized in Table 12. It compares cell surface marker expression on PBMCs before and after 
treatment to monitor T-regulatory cells (T-reg) and myeloid-derived suppressor cells (MDSC) in 
the blood at baseline and following treatment (Day 29 and Day 85) in patients treated with 
tremelimumab and IFN-α. 
 
 
 
 
 
 
 
 
 
 
 
 
 48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In terms of MDSC, there was significant decrease in the percentage of all MDSC 
populations at D29, most significantly for the monocytic MDSC type (HLA-DR+ low/CD14+) at 
D29 (p<0.0001) and D85 (P=0.001), as illustrated in Figures 12. Less significantly we noted 
decrease in the percentage of lymphoid type MDSC (Lin1-/HLA-DR-/CD33+/CD11b+) at D29 
(p=0.055) and D85 (p=0.07) and these appeared to be more significantly decreased in responders 
(CR/PR) versus non-responders (SD/PD), at D85 (p=0.048), as illustrated in Figures 13 and 14. 
Figure 11. IFN-Treme. Significant increase in the percentage of CD4+CD25hi+ CD39+ 
T-reg at day 85 (p=0.018) and less significantly at day 29 (p=0.09) following IFN-
α/tremelimumab as compared to baseline 
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There was also decrease in the frequency of monocytic MDSC type (Lin1-/HLA-DR-
/CD33+/CD11b+) at D29 (p=0.04), Figure 15.   
 
Figure 12. IFN-Treme. Significant decrease in the percentage of the monocyte MDSC type (HLA-DR+ 
low/CD14+) at day 29 (p<0.0001) and day 85 (p=0.001) following IFN-α/tremelimumab compared to 
baseline 
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Figure 13. IFN-Treme. Decrease in the percentage of the lymphoid MDSC type (Lin1-HLA-DR-
CD33+CD11b+) at day 29 (p=0.055) and day 85 (p=0.07) following IFN-α/tremelimumab compared to 
baseline 
 
Figure 14. IFN-Treme. Change in the percentage of lymphoid type MDSC (Lin1-HLA-DR-CD33+CD11b+) 
at D85 (completion of one course of IFN-α/tremelimumab) compared to baseline plotted by tumor response 
status (CR/PR versus SD/PD) 
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6.3.1.6 Correlations between baseline serum cytokines/soluble proteins and suppressor 
cellular levels 
There was significant correlation between baseline serum IL-6 and CRP (Spearman's 
correlation; p<0.0001). There was correlation between baseline CRP and monocytic MDSC type 
(HLA-DR+ low/CD14+) (Spearman's correlation; p=0.067), and between baseline CRP and 
CD4+CD25hi+FoxP3+ T-reg (Spearman's correlation; p=0.02). 
 
 
Figure 15. IFN-Treme. Decrease in the percentage of monocytes type MDSC (Lin1-/HLA-DR-
/CD33+/CD11b+) at D29 (p=0.04) and D85 (p=NS) following IFN-α/tremelimumab compared to 
baseline 
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6.3.2 Safety and immunogenicity of vaccination with multi-epitope peptide vaccine 
containing MART-1 (26-35, 27L),  gp100 (209-217, 210M), and tyrosinase (368-376, 370D) 
peptides given in-oil-adjuvant with the combination of TLR-9 agonist PF-3512676 and 
GMCSF for HLA-A2+ patients with recurrent inoperable stage III or stage IV melanoma 
6.3.2.1 Induced Autoimmunity 
Among 18 patients tested, none had evidence of induced autoimmunity (by our 
definition) at day 50 or day 90. 
 
6.3.2.2 CRP/ALC 
Wilcoxon rank-sum test was used to compare baseline level of ALC and CRP in patients 
whose best response was SD/PR and those whose best response was PD. No statistically 
significant differences were found. The corresponding p-values were 0.30 and 0.76. These are 
illustrated in Figure 16 where the boxplots show a clear trend towards a lower baseline ALC in 
patients with PD as compared to patients with PR/SD.  
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6.3.2.3 Multicolor flow cytometry comparing cell surface marker expression on PBMCs 
before and after treatment to monitor T-regulatory cells (T-reg) and myeloid-derived 
suppressor cells (MDSC) in the blood at baseline and following treatment  
 
T-regs were defined as cells expressing: (1) CD4+CD25hi+FoxP3+ or (2) 
CD4+CD25hi+CD39+ 128. 
 
MDSC were defined as cells expressing: (1) Lin1-/HLA-DR-/CD33+/CD11b+ (lymphoid 
type MDSC), (2) Lin1-/HLA-DR-/CD33+/CD11b+ (monocytic type MDSC) or (3) HLA-DR+ 
low/CD14+ (monocytic type MDSC)129, 130. 
Figure 16. Vaccine. This figure illustrates the distribution of baseline absolute 
lymphocyte count (ALC) and baseline C-reactive protein (CRP) by clinical benefit 
(PR/SD versus PD) 
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Changes in T-reg and MDSC were compared between baseline and Day 50 (following 4 
vaccinations) and Day 90 (following 8 vaccinations), that is the time points when PBMC were 
collected for IFN-γ ELIspot monitoring of the antigen specific cytotoxic T cell response. There 
were no significant changes in the percentage of Tregs or MDSC between baseline and D50 or 
D90, except for a trend towards a decreased percentage of other monocytes MDSC (HLA-DR+ 
low/CD14+) at day 50 (p=0.07), illustrated in Table 13 and Figures 17 and 18. 
 
Table 13. Vaccine. Multicolor flow cytometry comparing cell surface 
marker expression on PBMCs before and after treatment to monitor T-
regulatory cells (T-reg) and myeloid-derived suppressor cells (MDSC) in the 
blood at baseline and following treatment (day 50 and day 90) in patients 
treated with multi-epitope vaccine in adjuvant with PF-3512676 and 
GMCSF 
 
Change at 
Day 50 +/- se 
p-
value 
Change at 
Day 90 +/- se 
p-
value 
T-Regs     
CD4+ % 2.12 +/- 1.784 0.255 2.25 +/- 2.38 0.554 
CD4+CD25+ % 0.18 +/- 0.759 0.823 
0.49 +/- 
0.981 0.625 
CD4+/CD25hi+ % 
0.075 +/- 
0.357 0.559 close to 0 
close 
to 1 
CD4+CD25hi+ 
Foxp3+ % 
-5.01 +/- 
4.789 0.867 
-7.01 +/- 
8.334 0.625 
CD4+CD25hi+CD39+ 
% 
-0.71 +/- 
2.004 
close to 
1 
-0.36 +/- 
2.886 0.77 
MDSC     
% lymphocytes Lin1-
/HLA-DR-
/CD33+/CD11b+ 0.9 +/- 1.407 0.368 
0.58 +/- 
1.462 0.77 
% monocytes Lin1-
/HLA-DR-
/CD33+/CD11b+ -2.0 +/- 4.575 0.898 
1.57 +/- 
4.092 0.922 
% monocytes HLA-
DR+ low/CD14+ 
-9.35 +/- 
4.663 0.07 
-3.95 +/- 
8.095 0.846 
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Figure 17. Vaccine. This forest plot presents graphically the multicolor flow cytometry data 
summarized in Table 13. It compares cell surface marker expression on PBMCs before and after 
treatment to monitor T-regulatory cells (T-reg) and myeloid-derived suppressor cells (MDSC) in the 
blood at baseline and following treatment (day 50 and day 90) in patients treated with multi-epitope 
vaccine in adjuvant with PF-3512676 and GMCSF 
 
 
 
 
 
 
Figure 18. Vaccine. Decrease in the percentage of other monocytes MDSC type (HLA-DR+ 
low/CD14+) at day 50 compared to baseline (p=0.07) and day 90 following multi-epitope vaccine in 
adjuvant with PF-3512676 and GM-CSF 
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7.0 DISCUSSION 
 
 Non-tumor specific immunotherapy utilizing interleukin-2 (IL-2) and more recently 
ipilimumab (for metastatic melanoma) and interferon-α (for surgically resected melanoma) have 
produced the most significant results in the management of this disease leading to regulatory 
approval.3-5 On the other hand, results from antigen specific immunization modalities have been 
modest and have not yet translated into meaningful clinical benefits. These include cancer 
vaccines designed to increase immune recognition of tumor cells and to enhance the antitumor 
effector immune response through lymphocyte activation.3, 6, 7 To date, several tumor vaccination 
studies have demonstrated successful antitumor immunization but with modest clinical benefits 
while others have shown that tumors may progress in immunologically competent hosts in the 
face of existing and measurable anti-tumor immune responses.6 Therefore, although the 
components necessary for mounting an effective anti-tumor immune response may be present in 
patients with melanoma, the host usually fails to arrest tumor progression. In this project, I have 
conducted and compared 2 model studies representing alternative immunotherapeutic approaches 
(non-antigen specific compared to tumor antigen specific) meant to overcome tumor immune 
evasion and conducted separately in a similar patient population.  
First, I tested the combination of IFNα-2b and CTLA4 blockade with tremelimumab as a 
non-tumor antigen specific immunotherapy for advanced melanoma. Second, I tested peptide 
vaccination against melanoma lineage antigens given with a potent adjuvant combination of the 
TLR-9 agonist PF-3512676 and GM-CSF. My primary goals were to test efficacy and safety of 
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both regimens. In addition, I pursued the evaluation of select correlate biomarkers of immune 
tolerance and its reversal and immune monitoring of the host suppressor cellular response within 
both studies to better understand our clinical observations. Here, I evaluated candidate serologic 
and/or clinical biomarkers that are of potential prognostic value (induced autoimmunity: as a 
clinical marker of successfully overcoming immune tolerance) or therapeutic predictive value 
(CRP, IL-6, VEGF: as markers of enhanced immune tolerance). I evaluated the value of baseline 
ALC (lymphopenia as a marker of enhanced immune suppression) as a baseline therapeutic 
predictive biomarker for immunotherapy. Lastly, based on our clinical observations on both 
studies, I tested the hypothesis that tumor antigen nonspecific IFN-α/tremelimumab therapy 
when compared to the anti-melanoma peptide vaccine would more significantly downregulate 
the host suppressor immune response.      
 
Clinical Activity and Safety 
Table 14 summarizes the clinical efficacy data as observed in the IFN-α/tremelimumab study 
and the multi-epitope vaccine study. The IFN-α/treme study tested a strategy for overcoming 
tumor-induced immune suppression that builds upon the success of IFN-α and its 
immunomodulatory qualities in the adjuvant setting 43, 46 through downregulation of the CTLA4 
suppressive regulatory elements.36 IFN-α at high dosage (HDI) has been shown to play a critical 
role in interrupting tumor immune tolerance both improving tumor immunogenicity and 
increasing DC activation and survival.42, 131 IFN-α upregulates major histocompatibility complex 
(MHC) antigen processing and costimulatory molecules leading to efficient self-antigen 
presentation to previously quiescent low-affinity autoreactive T-cells.42, 131  IFN-α has been 
reported to affect almost all stages of myeloid DC generation, maturation, differentiation and 
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function47 increase activation and survival of DCs, which in turn promote maturation of effector 
CD8 T cells.42, 131  Therefore, IFN-α has a significant impact on conditioning the tumor and 
antigen-presenting cells (APCs) by making the tumor more immunogenic and enhancing antigen 
cross presentation, jointly leading to better anti-tumor immunization. Moreover, in their 
immature state, IFN-treated DCs induce a ‘polarized’ Th1 cytokine microenvironment.48 
Similarly, IFNs polarize lymphocytes towards the pro-inflammatory Th1 phenotype.49-51 This 
promotes a significant impact of  type-I IFNs in the cytotoxic T cell compartment, inducing 
potent antitumor cell-mediated cytotoxicity,52 and promoting NK cell-mediated proliferation and 
cytotoxicity.53 Type-I IFNs have been shown to activate APCs to produce chemokines that 
differentiate naïve CD4 T-cells, expand non-polarized antigen-primed Th1 T-cells, and cooperate 
with NK cells to induce anti-tumor CD8 T-cells to create a polarized Th1-biased tumor micro-
environment in which host effector response against melanoma is possible.132 This IFN-induced 
Th1 bias can be detected in melanoma patient circulation as an upregulation of the pro-
inflammatory cytokine response (Th1 polarization) as demonstrated in the adjuvant E1694 trial.46 
In addition, locally produced type-I IFNs induce the expression of integrins and chemokine 
receptors and recruitment of NK cells and macrophages leading to Th1 rather than Th2 
lymphocyte traffic to the tumor site.132 This has been demonstrated clinically where responding 
patients had significantly greater increases in intra-tumor CD11c+ DCs and CD3+ T-cells in a 
neoadjuvant melanoma study of HDI.13 Therefore, IFN-α induces a Th1 shift in immunity, 
promotes antitumor cell-mediated cytotoxicity and attracts Th1 lymphocyte traffic to the tumor, 
while increasing cellular expression of MHC, making tumor cells better targets for cell-mediated 
immune attack. However, this potent anti-tumor impact of IFN-α can still be suppressed by 
tumor tolerogenic mechanisms explaining the limited clinical activity of IFN-α as monotherapy 
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in metastatic melanoma.133-136 Combination with CTLA-4 blockade may alter this balance, 
downregulating the CTLA4 suppressive regulatory elements and possibly releasing inhibitory 
influences on activated CD25-expressing CD4 and CD8 effector cells, and thus, increasing their 
antitumor response. CTLA4 is a key element in immune tolerance and the main negative 
regulator of T cell-mediated antitumor immune responses where preclinical studies suggested 
that it serves as a natural braking mechanism for T-cell activation.21-24 The inhibitory signal 
produced by CTLA4 is therefore blocked by anti-CTLA4 mAbs (tremelimumab or ipilimumab), 
and T-cell activation is enhanced.25, 27, 31-33 Tremelimumab has been demonstrated to have a 
significant immune modulating role, unlocking the immune response by disrupting CTLA‐4, 
enhancing pro-inflammatory T-cell cytokine production54 and increasing T-cell infiltration in 
responding tumors.55 Therefore, IFN-α and tremelimumab may have an additive or a synergistic 
effect promoting tumor elimination. The currently tested combination of HDI and tremelimumab 
was relatively well tolerated with AEs that are expected and manageable. The frequency of AEs 
was not worse than those reported with HDI, tremelimumab or ipilimumab monotherapy.4, 77 The 
clinical activity is clearly promising by all measures analyzed in this study including durable RR 
(26%), PFS (median 6.4 months), OS (median 21 months) as well 1-year OS rate as analyzed by 
the Korn model (62% observed versus 21% predicted, p<0.0001). These results compare 
favorably to monotherapy with HDI,133-136  tremelimumab137 or ipilimumab.4 IFN-α was the first 
recombinant cytokine to be investigated clinically for the therapy of advanced metastatic 
melanoma yieldeding response rates of about 16% and responses were observed as late as 6 
months from initiation of therapy. However, the median duration of response was only about 4 
months.133-136 The ipilimumab-Gp100 phase III study that lead to recent FDA approval of 
ipilimumab for advanced inoperable melanoma randomized 676 pretreated patients. The RR was 
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5.7% (ipilimumab + gp100), 10.9% (ipilimumab + placebo), 1.5% (gp100 + placebo). Median 
OS increased from 6.4 months to 10.0 months with the addition of ipilimumab to gp100. The 
1year survival rates were 44% (ipilimumab + gp100), 46% (ipilimumab + placebo), 25% 
(ipilimumab + placebo).4 Similarly, tremelimumab has shown promising clinical activity in 
earlier trial testing in advanced melanoma that has lead to a subsequent phase III clinical trial 
(A3671009) in patients with treatment-naive advanced melanoma comparing tremelimumab (n = 
328) to standard-of-care chemotherapy (n = 327) with either dacarbazine or temozolomide. 138 
Although this study was halted for futility, the majority of responses to tremelimumab were 
durable and median survival was 12.02 months. Therefore, I conclude that the level of activity 
noted in this single arm phase II study warrants further testing in a randomized trial, and also 
supports the testing of ipilimumab in combination with IFN-α, preferably in a randomized phase 
II study.  
 
Cancer vaccination has the unique advantage of targeting the host immune response 
against tumor and creating melanoma specific immunity while potentially minimizing unwanted 
non-specific autoimmunity.7 However, tumor vaccination approaches have generally had limited 
clinical efficacy in melanoma despite solid preclinical data and the novel immunization strategies 
employed.6 One strategy to improve immunization outcomes is the testing of new and potent 
immunization adjuvants such as PF-3512676 and GM-CSF given in combination in oil-adjuvant 
as tested in this study with the multiepitope peptide vaccine for which significant data exist in the 
context of E1696 trial.6 In this study we have successfully immunized 9 (8 at day 50 and 1 at day 
90) out of 20 patients evaluable for immune response assessment which approaches the target of 
at least 9 ELISPOT positive patients based on the original design. Therefore, I consider this 
 61 
vaccination regimen to be potentially worthy of further study. In addition, I consider this potent 
adjuvant combination administered locally with the vaccine to be worthy of further testing with 
this and other vaccines. Our clinical data build upon evidence from preclinical studies supporting 
this vaccination adjuvant combination.91, 92 My conclusion is also supported by the data that GM-
CSF when administered locally with tumor vaccines has been found to have beneficial effects on 
vaccine immune responses believed to be due to its effects on DCs 69, 88, 94, 95, including evidence 
that GM-CSF attracts DCs to the site of vaccine injection.96, 97 In our combination approach, this 
would be coupled with the impact of the TLR9 agonist on enhancing plasmacytoid dendritic cell 
(pDC) maturation, increasing their expression of MHC class I and II molecules and co-
stimulatory molecules, and promoting Th1-type immune responses.98, 99 Clinically, 10 out of 21 
patients had either a response or stable disease, although of limited duration (range 2-7 months). 
Median PFS was 1.9 months and median OS was 13.4 months compared to a historical control of 
median PFS of 1.7 months (95% CI, 1.6 months to 1.8 months) and median OS of 6.2 months 
(95% CI, 5.9 months to 6.5 months).20 It is noteworthy that 11/21 patients evaluable for efficacy 
had M1c disease. In addition, 7/21 had prior treated brain metastases and among these, 6/7 had 
subsequent disease progression in the brain. Brain metastases in patients with stage IV melanoma 
have been reported in at least 18% to 46% of patients139, 140, with roughly twice this prevalence 
reported in autopsy series140-143. Brain metastases are a major cause of morbidity and mortality, 
leading directly to death in as many as 95% of melanoma patients with CNS spread of the 
disease 140, 143, 144. Definitive local treatment can be achieved with surgery or stereotactic 
radiosurgery (SRS) with or without WBRT in carefully selected patients with limited disease and 
may prolong survival 145-150. We conclude that the clinical activity observed with this vaccination 
regimen in this poor prognosis population is notable. However, the overall clinical activity of the 
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proposed regimen in this population is clearly suboptimal. In regards to the safety of this 
regimen, there were no regimen-related grade 3 or higher AEs. The vaccination regimen was 
relatively very well tolerated when compared to other systemic immunotherapeutic agents for 
melanoma such high dose IL-2 and anti-CTLA4 monoclonal antibodies or IFN-α.  
 
Comparing both approaches, the multiepitope vaccine regimen utilizing CpG and GM-
CSF as a potent adjuvant combination has successfully immunized 9/20 patients including 6 
patients with SD or PR. Although we have seen clinical activity in 48% of patients (2PR and 
8SD), the overall clinical activity has been modest when assessing the durability of the tumor 
responses and when compared to the level and durability of clinical activity we observed with 
the non-tumor specific approach utilizing IFN/treme. Our non-antigen specific 
immunotherapeutic approach relied on a strategy to enhance the patient’s antitumor response 
using an antibody that blocks one of the immunoregulatory mechanisms that are able to suppress 
host responses to TAAs. In fact, it is well supported that the induction of effective antitumor 
immunity in patients with cancer will require approaches aiming at the protection of anti-tumor 
immune cells (e.g. those induced/enhanced by IFN-α) from the inhibiting effects of myeloid-
derived suppressor cells, regulatory T cells or tumor derived inhibitory factors thus enhancing 
effector functions. In addition, our strategies should be aimed at prolonging survival of central 
memory T cells, thus ensuring long-term protection.2 The post therapeutic induction of 
autoimmunity appears to correlate with successful reversal of tumor immune tolerance in the 
IFN/treme study while no such observation was made in the vaccine study. The lack of evidence 
of induced autoimmunity against the 6 autoantigens tested in the vaccine study may support the 
hypothesis that tumor specific vaccination has the potential of focusing the immune response 
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while minimizing non-specific autoimmunity that limits therapy with other non-specific 
immunotherapeutic agents such as anti-CTLA4 antibodies, IL-2 or IFN-α.19, 58-70, 106. On the 
other hand, it may be due to the lack of potent modulation of immune tolerance or the suboptimal 
cross reactivity with tumor by the peptide activated T cells.4, 151 The relatively very good safety 
profile of the vaccine study and the rationale for focusing the immune response to melanoma 
makes the vaccine regimen a good candidate for combinations with other immunotherapeutic 
agents with superior clinical activity in melanoma such CTLA4-blockade with tremelimumab or 
ipilimumab where autoimmunity in the form of immune related AEs are potentially serious AEs 
limiting continued therapy. Other candidates for future combinations with the vaccine regimen 
that may enhance the patient’s antitumor response are other monoclonal antibodies (mAbs) that 
target other immunoregulatory checkpoints that are able to suppress/enhance host responses to 
tumor associated antigens (TAAs) such as anti-CTLA44, 152, anti-PD1 and anti-PD-L1 blocking 
mAbs153-155  as well as CD40156, OX40157 and CD137 (4-1BB)158 agonist mAbs. The use of 
antibodies that modulate these immunoregulatory mechanisms appear to be among the most 
promising strategies to enhance the patient’s antitumor response prolonging T-cell activation, 
restoring T-cell proliferation, and thus amplifying T-cell-mediated immunity.4 Interestingly, it 
has been reported that tumor antigen-specific CD8 T cells infiltrating tumor, including MART-
1/Melan-A melanoma antigen-specific CD8 T cells express high levels of PD-1 and are 
functionally impaired, in contrast to T cells in normal tissues and peripheral blood T 
lymphocytes.159 These findings suggest that the tumor microenvironment can lead to up-
regulation of PD-1 on tumor-reactive T cells and contribute to impaired antitumor immune 
responses.159 Therefore, a vaccination strategy combined with an anti-PD-1 blocking mAb has 
the potential of improving clinical efficacy to this vaccination approach. 
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Associated Biomarkers 
Identification of biomarkers that are predictive of therapeutic benefits would enable the 
better selection of patients in order to treat only those who are most likely to benefit from 
therapy, while sparing those less likely to benefit from the significant toxicities associated with 
treatment. This is especially important with anti-CTLA4 mAb therapy as well as IFN-α that 
induce durable clinical benefits in a group of patients while they are associated with significant 
toxicity in the majority of patients treated.  
 
Clinical evidence of autoimmunity was reported as a post treatment correlate of 
improved outcome for patients receiving high dose IL-2 in melanoma.160  In this setting, 
autoimmunity induced as a collateral event in association with antitumor effects noted with IL-2 
has been more carefully correlated with the antitumor effects of IFN-α and with ipilimumab 
suggesting that autoimmunity against non-tumor antigens in the host may accompany anti-tumor 
responses and be related to the abrogation of host immune tolerance to the tumor.4, 58  It is 
noteworthy, that the superior clinical activity we observed in IFN/treme study has been 
associated with a correlation between induced autoimmunity and clinical benefit in this study. 
No such relationship or trend was noticed in the vaccine study. Here, the induction of 
autoimmunity by IFN-Treme appears to be a potential surrogate marker of more significant 
reversal in immune tolerance or reversing immune suppression that may have blocked the 
autoimmunity (cross presentation) through the promoting effects of IFN-α and tremelimumab. 
On the other hand, it is possible that the use of a multiepitope vaccine given with potent 
immunologic adjuvant has lead to focusing of the immune response to affect tumor primarily. 
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However, given the suboptimal clinical activity in the vaccine study, it is also possible that the 
peptide activated T cells induced by the vaccine have suboptimal cross reactivity with tumor.4, 151 
Therefore, based on our findings in the IFN-treme study and similar observations I hypothesize 
that the prevention of melanoma relapse and mortality with IFN-treme is associated with 
superior immune modulation (compared to the vaccine regimen) that may more significantly 
increase resistance to melanoma.19, 58-70, 106 This immunotherapeutic induction of autoimmunity 
may provide a useful surrogate biomarker of therapeutic benefit to be evaluated in future studies. 
Studies of autoimmunity and its genetic determinants may help identify patients most likely to 
benefit from immunotherapies associated with autoimmunity, such as IFN-α, IL-2 and the anti-
CTLA4 mAbs ipilimumab and tremelimumab.   
 
Interestingly, I have found a significant predictive value for baseline CRP in the IFN-
Treme study but not in the vaccine study. For first detection of melanoma stage IV disease, 
serum CRP has been shown to be potentially superior to conventional LDH measurement.108 As 
interesting is a potential role for CRP in mediating immune tolerance. CRP is synthesized by 
hepatocytes in response to IL-6 during inflammation.109 CRP binds to phosphocholine (PC) and 
related molecules on microorganisms and plays an important role in host defense. However, a 
more important role may be the binding of CRP to PC in damaged membranes. CRP increases 
clearance of apoptotic cells, binds to nuclear antigens and by masking autoantigens from the 
immune system or enhancing their clearance, CRP may prevent autoimmunity.109 In this study, 
we have found significant correlation between baseline serum IL-6 and CRP. We have seen 
correlation between baseline CRP and monocyte MDSC type (HLA-DR+ low/CD14+), and 
between baseline CRP and CD4+CD25hi+FoxP3+ T-reg. These observations support a value for 
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CRP as a marker of enhanced immune tolerance and while it acts as a tolerogenic inducible 
serum protein in the setting of inflammation, 109, 110 it may play a similar role in mediating tumor 
tolerance (in this case CRP is induced by tumor derived IL-6). Interestingly, a study utilizing a 
human hepatoma cell line showed that IFN-α inhibits CRP promoter activity and CRP 
secretion.111 Therefore, our ability to demonstrate a significant association between baseline CRP 
level and therapeutic benefit provides a potential baseline predictive biomarker to be validated in 
larger studies. Second, it potentially demonstrates the impact of IFN-α on reversing immune 
tolerance mediated by CRP if patients with higher baseline CRP are shown to benefit from the 
tremelimumab-HDI combination (cut off of 2.7 ULN with IFN-Treme) where a study with 
tremelimumab monotherapy reported CRP at 1.5 ULN or less as a predictor of response.107  
 
Lymphopenia is a commonly observed laboratory finding in patients with advanced 
cancers and correlated to poor prognosis in terms of overall and progression-free survival in 
patients with different cancer types, including breast cancer, sarcoma,  lymphoma and colorectal 
cancer. 114-118 In a pooled analysis of 3 studies testing ipilimumab in metastatic melanoma, higher 
post-therapeutic peripheral blood ALC were significantly associated with clinical activity.119-121 
Similarly, in another analysis of 51 evaluable patients who received ipilimumab at a single 
institution, ALC also correlated with clinical benefit. Patients with an ALC ≥1000/uL after 2 
ipilimumab doses (Week 7) had a significantly improved clinical benefit rate and median OS 
compared to those with ALC <1000/uL (51% vs 0%; 11.9 months vs 1.4 months).122 In the IFN-
Treme study, no patient with an ALC<1550/µL had an objective response and no patient with an 
ALC<1200/µL had either an objective response or stable disease by RECIST. A similar but non-
significant trend was noted in the vaccine study. Put together, baseline CRP and ALC may be 
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part of a baseline biomarker signature that may have a significant baseline predictive value to be 
validated in larger future studies or used as stratification factors in future studies. The lack of 
significant  therapeutic predictive values for CRP and ALC in the vaccine study compared to 
IFN/treme may have to do with the magnitude of the therapeutic benefit observed as it may not 
be possible statistically to show significant correlation between responders (only 2 in the vaccine 
study) and non-responders. Although, we have seen a trend toward an association between 
baseline ALC and disease control (response + SD) on the box plots. Our findings on ALC are 
interesting, but it is important to explore the impact of our regimen on specific T-cell 
components, including helper, cytotoxic and regulatory, tumor antigen-specific T-cell reactivity 
as well as myeloid-derived suppressor cell (MDSC) activity. It is equally important to investigate 
circulating cytokines such as IL-6, VEGF, TGF-ß1, IL-10, GM-CSF and prostaglandin E2 
known to be associated with Treg and MDSC activation, recruitment and function in relation to 
the cellular findings.124, 125  
 
The superior clinical antitumor activity of the IFN-Treme regimen compared to our 
vaccine regimen appears to be associated with the more significant modulation of circulating T-
regulatory cells as well as MDSCs by this regimen. There is apparent increase in 
CD4+CD25hi+ CD39+ Tregs (D85; p=0.018) but this is also associated with an increase in the 
overall CD4+ T cell population (D29; p=0.003). In parallel, we found no significant impact of 
the vaccine regimen of the frequency of circulating CD4+ T cells and/or T-regs. Regulatory T 
cells mediate homeostatic peripheral tolerance by suppressing autoreactive T cells. However, 
tumors appear to benefit from an immunosuppressive role mediated by Tregs that suppress 
tumor-specific T cell immunity and contribute to growth of human tumors.123 Tregs have been 
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shown to accumulate in human tumors and the peripheral circulation of patients with cancer.123 It 
is possible that the immunologic perception of TAA as self leads to Treg accumulation as a 
reaction to maintain immune tolerance. It is also hypothesized that as a response to 
immunosurveillance and editing, ongoing immunity is normally downregulated as antigen 
presentation and activation signals are reduced.1 T-regs contribute to down-regulation of immune 
activity of effector T cells and suppression in the tumor microenvironment by several 
mechanisms including the secretion of IL-10 and TGF-ß1 124, Fas/FasL and granzyme/perforin 
pathways mediated apoptosis of responder cells 161, and enzymatic (ectonucleotidases, CD39 and 
CD73) degradation of ATP to immunosuppressive adenosine which then binds to A(2a) 
receptors on effector T cells, suppressing their functions.128 Recently, it has been reported that 
human CD4+CD25highFOXP3+ Treg overexpress CD39.162, 163  CD4+CD39+and CD4+CD25high T 
cells express low levels of adenosine deaminase (ADA), the enzyme responsible for adenosine 
breakdown, and of CD26, a surface-bound glycoprotein associated with ADA. Human Treg 
characterized by the presence of CD39 and the low expression of CD26/ADA are responsible for 
the generation of adenosine, which plays a major role in Treg-mediated immunosuppression.128 
Therefore, we had an interest in looking at CD4+CD25hi+ CD39+ Tregs in the context of our 
studies and where we have seen downregulation following IFN-Treme. The expansion in 
CD4+CD25hi+ CD39+ Treg frequency following treatment with IFN-Treme is not surprising 
given the known mechanism of action of anti-CTLA4 mAbs and the blockade of CTLA4 on all 
CTLA4 expressing T cells, including T effector and Treg. When releasing the CTLA4 negative 
control on the lymphocyte cell cycle, lymphocytes proliferate, preferentially CD4+ T cells. T-reg 
express higher levels of CTLA4 in basal conditions. In fact, multiple other studies have reported 
expansion in T-reg frequencies or functions following treatment of cancer patients with 
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ipilimumab 164, 165 or tremelimumab.166 Maker et al. reported that the suppressive activity of T-
regs was not affected by the addition of 10 or 100 μg/ml ipilimumab in vitro to a co-culture of 
CD4+CD25+ T-regs and CD4+CD25− T effector cells at 1:1 ratio.165 On the other hand, Elkord 
et al reported that tremelimumab does not deplete T-regs in treated cancer patients, but expand 
Tregs in vitro expressing FoxP3 with no IL-2 release, suggesting them as “bona fide” T-regs.167 
Taken together with our data, I suggest that anti-CTLA4 mAbs induce anti-tumor immune 
responses mainly by directly inhibiting the CTLA4 suppressive effects on T effector cells 
leading to their expansion and prolonged activation and less so by affecting T-regs. 
 
Recent studies implicate MDSCs in the induction of CD8+ T cell tolerance in tumor-bearing 
hosts. MDSC are bone marrow-derived immature myeloid cells that are heterogeneous in nature 
and expand during cancer, inflammation and infection. They are increased in frequency in the 
peripheral circulation and tumors of nearly all cancer patients and have a remarkable ability to 
suppress T-cell responses.125 They suppress T-cell responses by a variety of mechanisms 
including regulation of the production of indoleamine-2,2-dioxygenase (IDO) by the tumor. IDO 
is involved in the catabolism of tryptophan, an amino acid essential for T-cell differentiation.168 
MDSC also induce T cell tolerance by producing an enzyme involved in L-arginine metabolism, 
arginase 1, as well as the activation of iNOS.169 MDSC appear to be recruited by tumor-derived 
soluble factors such as TGF-ß1, IL-10, VEGF, GM-CSF, IL-6 and prostaglandin E2 (PGE2). In 
the IFN/Treme study, we observed significant decrease in the percentage of all MDSC 
populations at day 29, most significantly for the monocytic MDSC type (HLA-DR+ low/CD14+) 
at day 29 (p<0.0001) and day 85 (P=0.001). Less significantly we noted decrease in the 
percentage of lymphoid type MDSC (Lin1-/HLA-DR-/CD33+/CD11b+) at day 29 (p=0.055) and 
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day 85 (p=0.07). There was also decrease in the frequency of monocytic type MDSC (Lin1-
/HLA-DR-/CD33+/CD11b+) at day 29 (p=0.04). In the vaccine study, similar to our observation 
with T-regs, MDSC were not significantly changed between baseline and day 50 or day 90, 
except for a trend towards a decreased percentage of monocytic MDSC type (HLA-DR+ 
low/CD14+) at day 50 (p=0.07). Overall, we note more significant modulation of the frequencies 
of circulating T-reg and MDSC by the IFN-Treme regimen compared to the vaccine. When 
looking in patient serum we saw correlations between baseline CRP and monocytic MDSC type 
(HLA-DR+ low/CD14+) that goes in parallel to the correlation between IL-6 and CRP. 
Therefore, it is possible that tumor derived factors such as IL-6, VEGF, TGF-ß1, IL-10, GM-
CSF, and prostaglandin E2 lead to the recruitment and expansion of MDSC and in the case of IL-
6 induce the secretion of CRP. We have seen that IL-6 significantly correlates with CRP, low 
CRP correlates with low MDSC and with the probability of response to IFN-Treme, while IFN-
Treme significantly downregulates MDSCs (and I suggest upregulates the antitumor effector 
response) and induces significant clinical benefits. 
 
 
 
8.0 CONCLUSIONS AND FUTIRE DIRECTIONS 
 
The IFN-Treme phase II study has met criteria for efficacy based on the original design 
for this trial (response rate) and also in relation to the model proposed by Korn et. al.  (significant 
improvement in 1-year OS rate predicted (21%)/ observed (62%); p≤0.0001). The combination 
of HDI and tremelimumab has tolerable and manageable toxicity in relation to the therapeutic 
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benefit observed. Testing in a randomized setting is therefore now warranted, both in the 
advanced metastatic disease setting, and also in the neoadjuvant and/or adjuvant setting, where 
IFNα has been the only available agent since its approval in 1995 (planned ECOG randomized 
phase II trial proposal in metastatic disease and UPCI 11-123 neoadjuvant ipilimumab-HDI trial 
for high risk operable disease).  Our vaccination regimen has a superior safety profile but inferior 
clinical efficacy as compared to IFN-Treme and is worthy of further testing with the same or 
alternative peptides (possibly cancer testis antigens), potentially in combination with mAbs that 
target immunoregulatory checkpoints, in an effort to improve clinical efficacy. Autoimmunity 
correlates with improved clinical outcome and possibly with significant reversal in immune 
tolerance. Studies of autoimmunity and its genetic determinants may help identify patients most 
likely to benefit from immunotherapies associated with autoimmunity, such as IFN-α, IL-2 and 
the anti-CTLA4 mAbs ipilimumab and tremelimumab (this is planned in the context of Spore 
Project1 with IFNα, UPCI 10-095 testing IL-2 and E1609 testing IFNα and anti-CTLA4 
ipilimumab; please see next paragraph). Baseline CRP and ALC are significantly predictive of 
therapeutic benefit of IFN-Treme and may serve as variables for stratification of future trials, 
once validated in a larger study (this is planned in the context of the proposed ECOG 
ipilimumab-HDI randomized trial and E1609). Collectively, our findings support more 
significant downregulation of the host suppressor immune response by the nonspecific IFN-
α/treme regimen as compared to the vaccine. There is apparent increase in CD4+CD25hi+ 
CD39+ Tregs (D85; p=0.018) but this is also associated with an increase in the overall CD4+ T 
cell population (p=0.003). In addition, we see parallel downregulation in several populations of 
MDSCs which may serve to reduce immune suppression. Autoimmunity induced as a collateral 
event in association with antitumor effects is noted with the IFN/treme regimen but not the 
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vaccine, in accordance with the differential ability of the two regimens to overcome self-
tolerance against melanocyte-related antigens. Studies of peripheral antigen-specific T-cell 
responses in the IFN-Treme are ongoing in the laboratory and will be correlated with host 
suppressor immune response. These immune monitoring/mechanistic studies are being validated 
in the context of UPCI 08-144 testing neoadjuvant ipilimumab and are planned in the context of 
the upcoming UPCI 11-123 testing neoadjuvant ipilimumab-HDI. Our findings will be validated 
in the context of the larger studies.   
 
Future therapeutic strategies will build on data obtained from these studies, both to refine 
immunotherapeutics designed to overcome tumor-induced immune suppression and tumor 
evasion and to identify biomarkers of prognostic and therapeutic predictive value. Additional 
approaches for clinical development may include combination strategies with other cytokines 
and monoclonal antibodies targeting 4-1BB (CD137), PD-1, and CD40 with or without 
melanoma-specific immunization. These could also be tested in combination with promising 
therapeutic approaches targeting groups of patients with specific activating mutations that drive 
malignant proliferation such as the V600E BRAF mutation and mutations and amplifications in 
the receptor tyrosine kinase c-kit. Testing of CTLA-4 blockade in the earlier adjuvant setting is 
planned in the upcoming Intergroup E1609 trial (Chair: A. Tarhini). The neoadjuvant setting 
with access to tumor tissue before and after neoadjuvant therapy provides an ideal opportunity to 
identify immunologic and histologic correlates of tumor response. This is ongoing in UPCI 08-
144 (PI: A. Tarhini), neoadjuvant ipilimumab trial with the goal of further validation of 
biomarker data in the context of E1609 adjuvant trial. Based on our results IFN-Treme, UPCI 
11-123 (PI: A. Tarhini) testing neoadjuvant ipilimumab and HDI combination will be launched 
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as a sequel to 08-144 (nearing completion). I have also proposed the combination of ipilimumab 
and HDI to be tested through ECOG in a randomized phase II trial based on IFN-Treme results. 
In parallel, immunogenetic determinants of autoimmunity induced by adjuvant IFN-α and IFN-α 
clinical benefits are planned as a corollary to the ongoing E1697 trial (Skin Spore Project1; Co-
leader: A. Tarhini). Biomarker and mechanistic data obtained in the context of IFN-Treme, 08-
144, Spore Project 1 and 11-123 (in the near future) will be validated in the context of E1609. In 
addition, building on the limited success of recombinant IL-2 in melanoma (5-6% durable 
response rate), a randomized multicenter phase II study has been initiated testing anti-VEGF 
therapy with VEGF Trap combined with IL-2 versus IL-2 monotherapy in a 2:1 randomization 
(Chair: A Tarhini). This study is being conducted through the NCI N01 mechanism based on 
data supporting a significant role for VEGF in mediating immune tolerance and where high 
serum VEGF predicts non-response to IL-2. Tissue and blood specimens are also being banked 
for the purpose of biomarker/mechanistic studies.  
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